

C

C I

B D

E D

M . GUAN W (C)

M . WANG L

N - D

M . QIN H

M . LI C

I N - D

M . ZHONG W

M . LIU N

A C

M . ZHONG W (C)

M . LIU N

M . LI C

N C

M . LIU N (C)

M . GUAN W

C

M . ZHONG W

M . LIU N

M C

M . GUAN W (C)

M . ZHONG W

M . QIN H

C

M . XU N (C)

M . XU Y

M . XIE T

M . QIAN C

W C

M . WANG J

M . WONG W C

A

M . GUAN W

M . WONG W C

A

BDO C S L P C P A LLP

L A H K L

C C

R O H O

PRC

S R

H R D

W , Z

PRC

C I

P P B H K

40/F, D S F C

248 Q ' R E

W

H K

HS R

C H K I S L

S 1712-1716, 17 F

H C

183 Q ' R E

W

H K

S C

2120

C W

I R

T : (86) 577 8877 1689

F : (86) 577 8878 9117

E : @

F H

P F D I

	2022 MB'000	F 2021 RMB'000 (R)	D 2020 RMB'000 (R)	31, 2019 RMB'000	2018 RMB'000
R	1,484,903	1,297,430	989,012	860,692	745,972
P	15,605	95,691	83,509	55,523	106,910
I	26,574	54,831	30,662	-17,295	-31,941
N	-10,969	40,860	52,847	38,228	74,969
N					
S	-24,221	44,036	64,961	57,289	80,596
N -	13,252	-3,176	-12,114	-19,061	-5,627

	2022 MB'000	A 2021 RMB'000 (R)	D 2020 RMB'000 (R)	31, 2019 RMB'000	2018 RMB'000
T	2,637,787	2,377,955	2,161,262	2,117,352	1,840,724
T	1,311,885	1,097,676	946,349	855,843	635,451
T	1,325,903	1,280,279	1,214,913	1,261,509	1,205,273
E					
C	1,201,585	1,208,264	1,122,248	1,164,484	1,120,995
N -	124,318	72,015	92,665	97,025	84,278

N : D R P , G () D 31, 2021) F , N F S -O

C

D S ,

F , B D W K H C , L , I
G D 31, 2022 (F 2022).

I 2022, COVID-19 (

G , G I ,
G - ,

S O P H C 2030 R
N P I 14 F N H P I
S C M 2022
P E D D (2022-2035) O 2022 C C
C P C S C
G ,

D , G
. I , G
. D R P , G
1,107 12,172 - 3,266
I ,
G COVID-19 . M ,
- COVID-19 COVID-19 , COVID-19

M D A

B R

I 2022, C H C I . W
G H C I . W
G
:

T G ' 2022. D R P ,
G ' W K H , G K H , Q K
H , Y K H Y K H . I ,
G K H , Q K H Y K H ,
G ' . I
P Y H , C '

M D A

On January 1, 2022, the company's total assets were 1,107 million yuan, and the total liabilities were 3,266 million yuan. In 2022, the company's total revenue was 12,172 million yuan, and the total profit was 1,107 million yuan. The company's operating income was 12,172 million yuan, and the total profit was 1,107 million yuan. The company's operating profit was 1,107 million yuan, and the total profit was 1,107 million yuan. The company's operating profit was 1,107 million yuan, and the total profit was 1,107 million yuan.

In 2022, the company's total assets were 1,107 million yuan, and the total liabilities were 3,266 million yuan. In 2022, the company's total revenue was 12,172 million yuan, and the total profit was 1,107 million yuan. The company's operating income was 12,172 million yuan, and the total profit was 1,107 million yuan. The company's operating profit was 1,107 million yuan, and the total profit was 1,107 million yuan. The company's operating profit was 1,107 million yuan, and the total profit was 1,107 million yuan.

B H

In 2022, the company's total assets were 1,107 million yuan, and the total liabilities were 3,266 million yuan. In 2022, the company's total revenue was 12,172 million yuan, and the total profit was 1,107 million yuan. The company's operating income was 12,172 million yuan, and the total profit was 1,107 million yuan. The company's operating profit was 1,107 million yuan, and the total profit was 1,107 million yuan. The company's operating profit was 1,107 million yuan, and the total profit was 1,107 million yuan.

In 2022, the company's total assets were 1,107 million yuan, and the total liabilities were 3,266 million yuan. In 2022, the company's total revenue was 12,172 million yuan, and the total profit was 1,107 million yuan. The company's operating income was 12,172 million yuan, and the total profit was 1,107 million yuan. The company's operating profit was 1,107 million yuan, and the total profit was 1,107 million yuan. The company's operating profit was 1,107 million yuan, and the total profit was 1,107 million yuan.

M E D I C A L

F

T G RMB1,484.9 R P , 14.4%
 2021. A , RMB1,366.8 ,
 13.6% 2021. D R P ,
 23.9% (2021: 25.4%). T G RMB352.9 ,
 7.3% 2021. D R P ,
 S C RMB-24.2 , -
 2022. T S C
 RMB41.1 . D R P , G
 RMB227.2 (2021: RMB193.9), 17.2% 2021.

R C R
 T G ; () ; ()
 ; ()
 T :

F D 31,
 2022 2021
 (MB'000) (RMB'000)

M E D I C A L

Item	2022 (RMB'000)	2021 (RMB'000)
Balance at the beginning of the year	1,425,005	1,229,996
Loss of income from special medical services	43,545	-18
Change in provisions	14,643	27,240
Balance at the end of the year	1,366,817	1,202,774

Note:

- (1) Loss of income from special medical services refers to the estimated unrecoverable charges for offering medical services by the Group to extremely deprived community members, low-end patients who are impoverished due to illness and other persons with special difficulties stipulated by the people's government at or above the county level (the "Provisional Policy") pursuant to relevant policies.

For the year ended December 31, 2022, the Group's balance of special medical services provisions was RMB1,425.0 million, an increase of 15.9% compared with RMB1,229.996 million at the end of 2021. The increase was primarily due to the increase in the balance of special medical services provisions for extremely deprived community members, low-end patients who are impoverished due to illness and other persons with special difficulties stipulated by the people's government at or above the county level (the "Provisional Policy") pursuant to relevant policies. The balance of special medical services provisions at the end of 2022 was RMB14.6 million, compared with RMB12.6 million at the end of 2021.

M		D		A			
T		B		R		G	
						F	D
						2022	31,
						(MB'000)	2021
							(RMB'000)
B	R					1,119,887	962,408
C						770,287	658,194
G						349,600	304,214
P							
B	R					305,118	267,588
C						269,828	238,918
G						35,290	28,670
B						1,425,005	1,229,996
C						1,040,115	897,112
G						384,890	332,884
D	R	P	, B	R	G		RMB1,425.0

M D A

T 40
4

，

B R

4G

F 4

M D A

DRP, BR RMB1,218.3, 15.6% 2021, : () G, 13.0%, Q KH, Y KH, TH KH, W NH, W CH, P C Y H, Y Y H J S H () G, 2.4%. T BR BR 85.5% (2021: 85.7%).

DRP, BR RMB206.7, 17.2% 2021, 30.9% BR BR 14.5% (2021: 14.3%).

DRP, BR RMB1,218.3, 15.6% 2021, 78.6% (2021: 78.2%) BR ; BR 14.0% 2021, 21.4% (2021: 21.8%) BR 12.8% (2021: 13.8%), BR 71.9% (2021: 69.3%).

C G, T G:

	F D 31,	
	2022	2021
	(MB'000)	(RMB'000)
P	339,777	310,090
E	390,107	321,207
D	33,584	42,283
D	99,553	75,386
C	63,747	53,470
T	27,588	25,595
O	85,759	69,081
C	1,040,115	897,112

M D A

D R P , G , RMB1,040.1 ,
15.9% 2021. I : () 9.6%
; () 21.5%
; () - -
32.1% 2021.

F ,
32.7% (2021: 34.6%). T
37.5% (2021: 35.8%). T
12.8% (2021:
13.1%).

R
T G ,
D R P ,
G RMB110.0 ,
RMB85.5 (2021: RMB51.6).

O
T G ,
D R P , RMB8.1 (2021: RMB23.6),
S Y H .

G P G P M
D R P , G RMB352.9 ,
7.3% 2021. T
RMB326.7 , 6.9% 2021. T
:

	F 2022	D 31, 2021
T	27.4%	29.6%
P	11.6%	10.7%
O	23.9%	25.4%
P	22.2%	24.7%
C	23.8%	25.4%

M D A

DRP, 2021, RMB43.6 G 23.8% (2021: 25.4%), 2.2

TS DRP, G RMB5.0 (2021: RMB5.8)

SE DRP, G RMB15.0 (2021: RMB10.3) T 1.1% G (2021: 0.9%)

A DRP, G T

	F 2022 (MB'000)	D 2021 (RMB'000)
E	111,252	100,510
D	24,761	22,117
C	29,187	13,014
T	4,359	2,835
O	36,328	37,896
	205,887	176,372

DRP, 2021, 16.7% G RMB205.9, RMB13.5 G 15.1% (2021: 14.7%).

M D A

R 2022 D 2021		E	
D R P , G	2022	D 31,	2021
	(MB'000)	(RMB'000)	
C 2022	18,899	16,487	
D 2021	9,803	8,059	
C I 2022	4,053	3,114	
O 2021	273	302	
	33,028	27,962	
D R P , G	RMB33.0	(2021:	

M I D A

2022年, 公司实现营业收入人民币6.7亿元, 较2021年增加51.1%。其中, 医疗服务收入人民币4.3亿元, 较2021年增加51.1%。药品销售收入人民币2.4亿元, 较2021年增加51.1%。

其他收入

2022年, 公司其他收入为人民币0.0亿元, 较2021年增加51.1%。

	2022 (人民币'000)	2021 (人民币'000)
销售费用	-15,927	-6,566
管理费用	18,063	7,075
研发费用	714	6,429
	2,850	6,938

2022年, 公司发生资产减值损失人民币2.9亿元, 较2021年增加51.1%。其中, 坏账损失人民币1.9亿元, 较2021年增加51.1%。

公允价值变动损益

2022年, 公司公允价值变动损益为人民币25.2亿元(2021年: 人民币2.1亿元), 较2021年增加51.1%。

资产处置收益

2022年, 公司资产处置收益为人民币10.3亿元, 较2021年增加51.1%。

M D A

Notes to the Financial Statements

As of December 31, 2022, the Company's total assets were RMB1,063 million, an increase of RMB300 million from RMB763 million at the end of 2021. Total liabilities were RMB854 million, an increase of RMB1,836 million from RMB671 million at the end of 2021. Total equity was RMB209 million, an increase of RMB1,739 million from RMB32 million at the end of 2021.

	December 31, 2022 (RMB'000)	December 31, 2021 (RMB'000)
Current assets	55	266
Non-current assets	7,436	9,470
Total assets	7,491	9,736
Current liabilities	1,063	300
Non-current liabilities	8,554	11,836
Total liabilities	9,617	12,136
Current equity	1,588	166
Non-current equity	3,928	3,333
Total equity	5,516	3,500
Total equity	2,071	1,739
Total equity	9,341	8,637

During the reporting period, the Company's total assets increased by RMB8.6 million, mainly due to the increase in non-current assets of RMB3.3 million. Total liabilities increased by RMB1.4 million, mainly due to the increase in current liabilities of RMB9.3 million. Total equity increased by RMB1.4 million, mainly due to the increase in non-current equity of RMB8.6 million.

Notes to the Financial Statements

During the reporting period, the Company's total assets increased by RMB26.6 million (2021: RMB54.8 million), an increase of 51.5% (2021: 170.3%) from 2021. Total liabilities increased by RMB170.3 million (2021: RMB57.3 million), an increase of 57.3% (2021: 170.3%) from 2021.

M D A

F P

I V

A D 31, 2022, ↓ ¥ 33.3 (D 31, 2021: RMB56.5),
¥ 22.8.

A R V

A D 31, 2022, ¥ 311.8 (D 31, 2021: RMB311.8),
¥ 22.8% (D 31, 2021, ¥ 22.8%).

D R P , ¥ 42 (2021: 37 ¥).

O R V P

A D 31, 2022, ¥ 69.4 (D 31, 2021: RMB41.8).

O N - F A

A D 31, 2022, ¥ 63.1 (D 31, 2021: RMB65.8). D R P , ¥ 2.7, ¥ 2.7.

C

A D 31, 2022, ¥ 152.5 (D 31, 2021: RMB43.8),
L Y H , L C H ,
Q Y H ¥ J S H .

R - - A

A D 31, 2022, - - ¥ 190.4 (D 31, 2021: RMB257.4),
¥ 54.2.
H Y H ¥ G R P .

A P

A D 31, 2022, ¥ 85.8 (D 31, 2021: RMB69.2).

M I N I S T E R

R A T I O N A L C A L C U L A T I O N

A T D E C E M B E R 31, 2022, T H E C O M P A N Y H A S A T O T A L A S S E T S O F R M B 29.9 B I L L I O N (A T D E C E M B E R 31, 2021: R M B 16.3 B I L L I O N).

O P E R A T I N G

A T D E C E M B E R 31, 2022, T H E C O M P A N Y H A S A T O T A L A S S E T S O F R M B 72.2 B I L L I O N (A T D E C E M B E R 31, 2021 (A T D E C E M B E R 31, 2021): R M B 57.3 B I L L I O N), W H I C H I N C L U D E S A T O T A L L I A B I L I T I E S O F R M B 17.0 B I L L I O N (A T D E C E M B E R 31, 2021: R M B 16.3 B I L L I O N).

L I A B I L I T I E S C A T E G O R I E S

T H E F O L L O W I N G T A B L E P R O V I D E S D E T A I L E D I N F O R M A T I O N O F T H E C O M P A N Y ' S L I A B I L I T I E S C A T E G O R I E S A T D E C E M B E R 31, 2022 A N D 2021:

	F E B R U A R Y 28, 2022	D E C E M B E R 31, 2021
	(R M B ' 0 0 0)	(R M B ' 0 0 0)
N O N - C U R R E N T A S S E T S	227,221	193,896
N O N - C U R R E N T L I A B I L I T I E S		

M D A

N G F A

D R P , RMB116.2 .

S I , A D

T G , R P .

A , G B

I

B B

A D 31, 2022, G RMB616.5 (D
31, 2021: RMB553.2), RMB339.4
RMB402.7 R P .

M D A

Exchange Rate

The Group uses the exchange rate of HKD to RMB. The exchange rate of HKD to RMB is 1:0.87 as of December 31, 2022, and 1:0.88 as of December 31, 2021.

As of December 31, 2022, the Group's total assets were RMB1,234.3 million, an increase of 49.7% from RMB824.3 million as of December 31, 2021. Total liabilities were RMB529.4 million, an increase of 46.2% from RMB362.4 million as of December 31, 2021.

Goodwill

As of December 31, 2022, the Group's goodwill was RMB443.3 million, an increase of 49.7% from RMB295.8 million as of December 31, 2021 (2021: RMB295.8 million).

Employee Compensation

As of December 31, 2022, the Group had 4,196 employees, an increase from 3,661 employees as of December 31, 2021. The average employee compensation was RMB529.4 million (2021: RMB443.3 million). Total compensation was RMB124.3 million (2021: RMB100.0 million). The Group's compensation policy is to attract and retain high-quality talent.

Shareholders

The Group's shareholders are listed in the following table. As of December 31, 2022, the Group has 10 shareholders, including 10 natural persons. The largest shareholder is Mr. Zhang Kangning, who holds 30.0% of the shares.

The Group's directors and supervisors are listed in the following table. The Group has 7 directors and 3 supervisors. The directors are Mr. Zhang Kangning, Mr. Wang Kangning, Mr. Li Kangning, Mr. Chen Kangning, Mr. Zhou Kangning, Mr. Wu Kangning, and Mr. Zhao Kangning. The supervisors are Ms. Sun Kangning, Ms. Li Kangning, and Ms. Wang Kangning.

The Group's independent non-executive directors are Mr. Ma Kangning, Mr. He Kangning, and Mr. Gu Kangning. The Group's independent non-executive supervisors are Ms. Sun Kangning, Ms. Li Kangning, and Ms. Wang Kangning.

M D A

I E I S , , 165 ,
1,818,529 . T , 23
, 180,516 . T ()
, 13 , 540,229 . A ,
8 , 79,274 . A ,
E I S 193 , 2,460,000
. T 3.2976%
C I . T 48
RMB10.47/ .

T E I S :

(1) P

T E I S
C I - , ,
G , S , C
C I . T E I S
S ,
C I A A .

(2) S P

(a) S P
A P G E I S .
D , S , G (,) , B , 36
B P I S .

() L P E I S
T P
B .

M D A

- (3) D E I S
- (a) F E I S
T C , I S
Pa . W I S Pa , Pa
S C T Pa ,
I S - . I S
Pa . T
. U - , Pa
I S
Pa .
- () S S E I S - - D
T I S E I S
S , C
- () A E I S
C
Pa 2,460,000 S E I S ,
3.30% C ,
4.45% - D S .

M D A

- (4) *V* , - *E I S*
- (a) *V* *E I S*
T *E I S* 10 *E I S* 2017 (. . A 26, 2018),
E I S .
- () *L* - *E I S*
T - *I S* *P* 48 , *E I S* .
- () *U* *E I S*
I S *E I S* 48 (J 28, 2022)
E I S (J 29, 2018); *I S* *E I S* .
- (5) *G* *E I S*
- () *T* *P* *P* *P* *P* .
- () *T C* *D N* *P* *G D* .
- () *T P* *D N* *C* *C*
- () *W* *C* *P* *C*
I S (*C*) *C*
- () *T C* *E I S* *S*
P , *P* , *S*
P , .

M D A

- (6) *G P E I S*
- (a) *G P E I S T G P I S*
RMB10.47 *S ; T G P I S* RMB10.47
S
- () *B G P E I S*
B S , G P RMB10.47 E I S C I S

M D A

F D 31, 2022, I S E I

S :

B

B

I

C P

I

G

()

C

L

G

D

G

G

D

31,

N G D G (H D) D) P (MB) 1, 2022 P P P P D 2022

D

M . WANG L () J 18, 35.95 J 28, 10.47 248,328 - 248,328 - - -

2021 2022

M . WANG H () J 18, 35.95 J 28, 10.47 95,511 - 95,511 - - -

2021 2022

S

M . SUN F () J 18, 35.95 J 28, 10.47 14,327 - 14,327 - - -

2021 2022

M . XIET J 18, 35.95 J 28, 10.47 4,776 - 4,776 - - -

2021 2022

O

M . XU Y (M . WANG H) J 18, 35.95 J 28, 10.47 28,653 - 28,653 - - -

2021 2022

M . WANG B (M . WANG L) J 18, 35.95 J 28, 10.47 4,776 - 4,776 - - -

2021 2022

M . WANG H () J 18, 35.95 J 28, 10.47 4,776 - 4,776 - - -

2021 2022

M . XU Q (M . XU Y) J 18, 35.95 J 28, 10.47 4,776 - 4,776 - - -

2021 2022

M . GUAN W () J 18, 35.95 J 28, 10.47 19,102 - 19,102 - - -

2021 2022

M . SUN H (M . WANG L) J 18, 35.95 J 28, 10.47 30,563 - 30,563 - - -

2021 2022

M . WANG H () J 18, 35.95 J 28, 10.47 4,776 - 4,776 - - -

2021 2022

M . ZHANG L (M . GUAN W) J 18, 35.95 J 28, 10.47 4,776 - 4,776 - - -

2021 2022

M . GUAN W () J 18, 35.95 J 28, 10.47 4,776 - 4,776 - - -

2021 2022

M D A

N	G	D	C P		B		G	()	C	L	I	D	31, 2022
			D	G	D	G							
		G	(H D)	D)	P	(MB)	1,2022	P	P	P	P		
S	**	A 20, 2018	38.80	J 28, 2022	10.47	133,715	-	133,715	-	-	-	-	-
C	*	A 20, 2018	38.80	J 28, 2022	10.47	1,684,814	-	1,684,814	-	-	-	-	-
		A 26, 2019	36.00	J 28, 2022	10.47	142,311	-	142,311	-	-	-	-	-
O	Y (*)	A 26, 2019	36.00	J 28, 2022	10.47	38,204	-	38,204	-	-	-	-	-
							2,454,632	-	2,454,632	-	-	-	-

E T P

T C
 ,
 . T C
)

Report of the Board

T B 31, 2022. G

P A

T G C, D

C R L R

T C , PRC C L , H K L R , SFO, H K C O , S , C T C B D .

L G M H L PRC 《中華人民共和國精神衛生法》, L P ' R C P B M H G 《中華人民共和國基本醫療衛生與健康促進法》(J 1, 2020), M R M I 《醫療機構管理條例》 R I M R M I 《醫療機構管理條例實施細則》.

T G . I

T C . T D G 2022 L P D .

P I P

F D 31, 2022, G .

U P I P O

SG

December 31, 2022, the Company's net assets were RMB233.5 million.

R

December 31, 2022, the Company's net assets were RMB233.5 million.

DR

As of December 31, 2022, the Company's net assets were RMB233.5 million.

PP&E

SD I F .Ma G ()0.0() .S ()0.0()0.6 ()0 5 ()0 6 ()0.5 ()0 5 ()0.5 ()0 .5 ()0 .5 ()0

Report of the Board

DIRECTORS

For the period from January 1, 2022, to December 31, 2022, the Board of Directors has completed its work in accordance with the provisions of the Company Law of the People's Republic of China, the Articles of Association, and the Regulations for the Board of Directors of the Company.

EXECUTIVE DIRECTORS

For the period from January 1, 2022, to December 31, 2022, the Executive Directors have completed their work in accordance with the provisions of the Company Law of the People's Republic of China, the Articles of Association, and the Regulations for the Board of Directors of the Company.

SECRETARY

For the period from January 1, 2022, to December 31, 2022, the Secretary has completed his work in accordance with the provisions of the Company Law of the People's Republic of China, the Articles of Association, and the Regulations for the Board of Directors of the Company.

SUPERVISORS

For the period from January 1, 2022, to December 31, 2022, the Supervisors have completed their work in accordance with the provisions of the Company Law of the People's Republic of China, the Articles of Association, and the Regulations for the Board of Directors of the Company.

DEPARTMENT

The Department of the Board of Directors is responsible for the following matters:

EXECUTIVE DIRECTORS

M. GUAN W (Chairman)

M. WANG L

M. WANG H (Secretary, since January 1, 2022)

NON-EXECUTIVE DIRECTORS

M. QIN H

M. LI C

INDEPENDENT NON-EXECUTIVE DIRECTORS

M. ZHONG W

M. LIU N

M. ZHAO X (since March 10, 2023)

S

T S R P :

M . XUN (C) (F ,19, 2022)

M . XU Y

M . XIE T

M . QIAN C

M . SUN F (C) (F ,15, 2022)

M . CHEN J (J ,17, 2022)

B R A K I F P

F , 2022, F H M D A , 31,

D ' S ' I T , A C

S R B - C T N F S - R

C , , , D S , , , D S , 31, 2022 R P .

C S ' I C S

S R B - C T N F S - R

, C S , , G C

M C

D R P , C , C

Report of the Board

NON-EXECUTIVE

At the 2022 Annual General Meeting of Shareholders, the Board of Directors of Wenzhou Kangning Hospital Co., Ltd. (the "Company") has reviewed the Company's financial statements for the year ended 31 December 2022, and the Company's financial position, performance, and cash flows for the year ended 31 December 2022. The Board of Directors has approved the financial statements for the year ended 31 December 2022, and the Company's financial position, performance, and cash flows for the year ended 31 December 2022.

The Board of Directors has also reviewed the Company's business performance for the year ended 31 December 2022, and the Company's financial position, performance, and cash flows for the year ended 31 December 2022. The Board of Directors has approved the Company's business performance for the year ended 31 December 2022, and the Company's financial position, performance, and cash flows for the year ended 31 December 2022.

DIRECTORS' CONFERENCE

The Board of Directors has reviewed the Company's financial statements for the year ended 31 December 2022, and the Company's financial position, performance, and cash flows for the year ended 31 December 2022. The Board of Directors has approved the financial statements for the year ended 31 December 2022, and the Company's financial position, performance, and cash flows for the year ended 31 December 2022.

The Board of Directors has also reviewed the Company's business performance for the year ended 31 December 2022, and the Company's financial position, performance, and cash flows for the year ended 31 December 2022.

DIRECTORS' INTERESTS

The Board of Directors has reviewed the Company's financial statements for the year ended 31 December 2022, and the Company's financial position, performance, and cash flows for the year ended 31 December 2022. The Board of Directors has approved the financial statements for the year ended 31 December 2022, and the Company's financial position, performance, and cash flows for the year ended 31 December 2022.

N	C	N	I	N	N	A P	A P	C	I	C	(1)	C	(1)
---	---	---	---	---	---	--------	--------	---	---	---	-----	---	-----

Report of the Board

I S S S

As of December 31, 2022, the Company has 336 shareholders, including 306 natural persons, 20 legal entities, and 10 SFOs. The Company's shares are listed on the Shanghai Stock Exchange. The Company's shares are held by 336 shareholders, including 306 natural persons, 20 legal entities, and 10 SFOs. The Company's shares are held by 336 shareholders, including 306 natural persons, 20 legal entities, and 10 SFOs.

Name	Shareholding Type	Shareholding Percentage	Number of Shares	Percentage of Total Shares	Percentage of Total Shares
				(1)	(1)
CHEN ERIC D S B (Central Enterprise Rural Industry Investment Fund Co., Ltd. (Central Enterprise Fund))	D S B		7,466,666(L)	13.51%	10.00%
SHANGHAI JINJIANG MANAGEMENT CENTER (LIMITED PARTNERSHIP) ⁽²⁾	D S I		4,540,000(L)	8.22%	6.09%
FAN Y ⁽²⁾	D S I		4,540,000(L)	8.22%	6.09%
SUN J ⁽²⁾	D S I		4,540,000(L)	8.22%	6.09%
SHANGHAI JINJIANG INVESTMENT MANAGEMENT CO., LTD. (Shanghai Jinpujian Equity Investment Management Co., Ltd.) ⁽²⁾	D S I		4,540,000(L)	8.22%	6.09%
WENZHOU JINJIANG INVESTMENT COOPERATIVE ENTERPRISE (LIMITED PARTNERSHIP) (Wenzhou Jinjiang Investment Cooperative Enterprise (Limited Partnership)) (Joint Investment)	D S B		4,540,000(L)	8.22%	6.09%
XU Y ⁽⁶⁾	D S I		5,785,350(L)	10.47%	7.76%
SHANGHAI TIANJI INVESTMENT L.P. (Shanghai Tianji Investment Co., Ltd.)	D S B		4,519,003(L)	8.18%	6.06%

Name	Company Type	Shareholding	Investment	Amount (RMB)	Percentage	
					Accounting	Capital
Shanghai Lejin Investment Partnership (Limited Partnership) ⁽³⁾	D	Shareholder	Investment	4,519,003(L)	8.18%	6.06%
LIN L	D	Shareholder	Investment	6,506,309(L)	11.77%	8.72%
Shanghai Zhengxin Valley Investment Management Limited Company (Shanghai Zhengxin Valley Investment Management Limited Company) ⁽⁴⁾	D	Shareholder	Investment	6,506,309(L)	11.77%	8.72%
Wan De Information Technology Co., Ltd. (Wan De Information Technology Co., Ltd.)	D	Shareholder	Investment	3,333,000(L)	6.03%	4.47%
Shanghai Hehua Yuan Enterprise Management Center (Limited Partnership) (Shanghai Hehua Yuan Enterprise Management Center (Limited Partnership))	D	Shareholder	Investment	3,333,000(L)	6.03%	4.47%
Wan De Influence Investment (Jiaxing) Partnership (Limited Partnership) (Wan De Influence Investment (Jiaxing) Partnership (Limited Partnership))	D	Shareholder	Benefit	3,333,000(L)	6.03%	4.47%
Qingdao Jinshi Lianou Investment Co., Ltd. (Qingdao Jinshi Lianou Investment Co., Ltd.)	D	Shareholder	Benefit	2,780,000(L)	5.03%	3.73%
Jinshi Investment Co., Ltd. (Jinshi Investment Co., Ltd.) ⁽⁵⁾	D	Shareholder	Investment	2,780,000(L)	5.03%	3.73%
OMAW LLC	HS	Shareholder	Investment	1,454,000(L)	7.52%	1.95%
OMG LLC	HS	Shareholder	Investment	2,150,900(L)	11.12%	2.88%
OMPF LLC	HS	Shareholder	Benefit	1,279,900(L)	6.62%	1.72%
OMPH II, L.P.	HS	Shareholder	Benefit	1,052,000(L)	5.44%	1.41%
UBS G AG	HS	Shareholder	Investment	1,029,400(L)	5.32%	1.38%
ZOU He (Zou He)	HS	Shareholder	Benefit	1,680,000(L)	8.69%	2.25%

Report of the Board

N :

(L): L

- (1) T 55,260,000 D S 19,340,300 H S (74,600,300 S) C D 31, 2022.
- (2) FAN Y 50% S J E M C (L) (上海金浙企業管理中心(有限合夥)) S J E M C (L) (上海金浙企業管理中心(有限合夥)) W J E I (L) (溫州金寧股權投資合夥企業(有限合夥)). SUN J 33.94% W J E I (L) (溫州金寧股權投資合夥企業(有限合夥)). S J J E I M C , L . (上海金浦健服股權投資管理有限公司) W J E I (L) . T , XV SFO, FAN Y , S J E M C (L) (上海金浙企業管理中心(有限合夥)), SUN J S J J E I M C , L . (上海金浦健服股權投資管理有限公司) D S W J E I (L) (溫州金寧股權投資合夥企業(有限合夥)) C
- (3) S L I L.P. (上海樂進投資合夥企業(有限合夥)) 99.99% S T I L.P. (上海檀英投資合夥企業(有限合夥)). T , XV SFO, S L I L.P. (上海樂進投資合夥企業(有限合夥)) D S S T I L.P. (上海檀英投資合夥企業(有限合夥)) C
- (4) S L V I M C , L (上海正心谷投資管理有限公司) (S S I I M C , L (上海盛歌投資管理有限公司)) S Q I M (L.P.) (上海乾剛投資管理合夥企業(有限合夥)) S T I L.P. (上海檀英投資合夥企業(有限合夥)). T , XV SFO, S L V I M C , L D S S I M (L.P.) (上海乾剛投資管理合夥企業(有限合夥)) (1,987,356 D S C S T I L.P. (上海檀英投資合夥企業(有限合夥)) C
- (5) Q J H I C , L . (青島金石灑汭投資有限公司) J I C , L . (金石投資有限公司). T , J I C , L . (金石投資有限公司) D S Q J H I I C , L . (青島金石灑汭投資有限公司) C , XV SFO.
- (6) M . WANG H N X K I M L.P. N E K I M (L) 50.62% 37.10%, , XV SFO, M . WANG H D S M . XU Y M . WANG H . M . XU Y D S M . WANG H XV SFO.

S , D 31, 2022, D , () D , S C , D 2 3 S S C D 2 3 P XV SFO, C S 336 SFO.



Report of the Board

C O N T E N T S

S E C T I O N I , R E P O R T O F T H E B O A R D , C O N T E N T S .

F O R M A T 10, 2023, M . Z H A O X I A O (M . Z H A O X I A O) A S T H E C H I E F A C C O U N T A N T . B E I J I N G C E N T R A L F I N A N C I A L F O U N D A T I O N M . Z H A O X I A O , C H I E F A C C O U N T A N T . H K L R : () B E I J I N G C E N T R A L F I N A N C I A L F O U N D A T I O N R 3.10 H K L R ; () B E I J I N G C E N T R A L F I N A N C I A L F O U N D A T I O N R 3.25 H K L R ; () B E I J I N G C E N T R A L F I N A N C I A L F O U N D A T I O N R 3.27A H K L R . O N M A Y 10, 2023, B E I J I N G C E N T R A L F I N A N C I A L F O U N D A T I O N M . J I N L I (M . J I N L I) A S T H E D E P U T Y C H I E F A C C O U N T A N T . B E I J I N G C E N T R A L F I N A N C I A L F O U N D A T I O N M . J I N L I A S T H E D E P U T Y C H I E F A C C O U N T A N T .

S E C T I O N I I P R O F I T

B E I J I N G C E N T R A L F I N A N C I A L F O U N D A T I O N C O N T R O L L E D S H A R E H O L D E R S D E P A R T M E N T , C O N T R O L L E D S H A R E H O L D E R S H K L R .

I N T E R N A T I O N A L R E P O R T

T H I S R E P O R T I S I N A C C O R D A N C E W I T H I T E M 13 O F T H E S T A T U T E O F T H E C O M P A N Y .

A C K N O W L E D G E M E N T S

T H A N K S T O B E I J I N G C E N T R A L F I N A N C I A L F O U N D A T I O N C O N T R O L L E D S H A R E H O L D E R S ' 2022 A N N U A L M E E T I N G A N D S A F E B O A R D .

A B O U T B D O

T H I S R E P O R T I S A U D I T E D B Y B D O C H I N E S E L P A C P A R T N E R S L L P (B D O) .

R 浙 康 宁 医 院 有 限 公 司 于 2022 年 10 月 16 日 召 开 了 2022 年 第 三 次 董 事 会 会 议 ， 会 议 决 议 通 过 了 公 司 2022 年 第 三 次 董 事 会 决 议 公 告 ， 公 告 内 容 请 参 见 本 报 告 第 18 页 。

A P 浙 康 宁 医 院 有 限 公 司 于 2022 年 10 月 16 日 召 开 了 2022 年 第 三 次 董 事 会 会 议 ， 会 议 决 议 通 过 了 公 司 2022 年 第 三 次 董 事 会 决 议 公 告 ， 公 告 内 容 请 参 见 本 报 告 第 18 页 。

W 浙 康 宁 医 院 有 限 公 司 于 2022 年 10 月 16 日 召 开 了 2022 年 第 三 次 董 事 会 会 议 ， 会 议 决 议 通 过 了 公 司 2022 年 第 三 次 董 事 会 决 议 公 告 ， 公 告 内 容 请 参 见 本 报 告 第 18 页 。

A 浙 康 宁 医 院 有 限 公 司 于 2022 年 10 月 16 日 召 开 了 2022 年 第 三 次 董 事 会 会 议 ， 会 议 决 议 通 过 了 公 司 2022 年 第 三 次 董 事 会 决 议 公 告 ， 公 告 内 容 请 参 见 本 报 告 第 18 页 。

F 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100

Report of the Board

(2) C 2020

(U : RMB,)

I	A	C	B
O	63,465,824	-12,878	63,478,702
T	542,683,617	-12,878	542,696,495
T	2,161,261,775	-12,878	2,161,274,653
O	76,603,400	-9,203,741	85,807,141
T	606,077,103	-9,203,741	615,280,844
T	946,349,216	-9,203,741	955,552,957
U	214,856,099	9,190,863	205,665,236
T	1,122,247,550	9,190,863	1,113,056,686
T	1,214,912,559	9,190,863	1,205,721,695
T	2,161,261,775	-12,878	2,161,274,653

(3) C 2021

(U : RMB,)

I	A	C	B
O	29,925,488	-12,878	29,938,366
T	609,602,623	-12,878	609,615,501
T	2,377,954,989	-12,878	2,377,967,867
O	57,319,524	-9,203,741	66,523,265
T	535,774,635	-9,203,741	544,978,376
T	1,097,675,868	-9,203,741	1,106,879,609
I	6,937,845	-12,878	6,950,723
U	257,098,624	9,190,863	247,907,761
T	1,208,263,897	9,190,863	1,199,073,034
T	1,280,279,120	9,190,863	1,271,088,257
T	2,377,954,989	-12,878	2,377,967,867

Opinions of the Independent Non-executive Directors

T - 25 \ C \ A S B E . T C \ T ,

Opinions of the Board

T B \ C \ A A ,

Opinions of the Supervisory Committee

T S \ C \ T S \ C

Opinions of the Audit Committee

T A C \ A S B E , \ A C T A C N XV F S - O \

T S :

I 2022, S C , PRC C L , A ,
S C , T B , S
C
D C S .

D R P , S C B C
C C

T S C - C R
P , D B ,

I 2023, S C - C
. T S C , S C
S C

F S C
XUN
C

Z , PRC
A 14, 2023

Corporate Governance Report

T C .T C CGC .
 T D , C , CGC R P .T C CGC .

T B

B C

A I P D , B D , D , - D
 D - D .T D
 D , S S M .T B
 C
 T B

T C H K L R .T C - D
 D R 3.13 H K L
 R .

A D , - D ,
 , B , B ,
 I - D A C , N C ,
 R C S R M C .

T CGC D C
 C .T D
 C

T C B .T C
 , D C
 C C ,
 B .T B .

Corporate Governance Report

R F D B

T B C I
- C D C
B .T
B .

T B C
, , , ()
, D
.F , A .

I , B A C , N C , R C
S R M C C
.F .

A D C S .

T C D

C C E

Corporate Governance Report

C 董 事 会 , S 董 事 会 C 董 事 会

O D 31, 2021, 董 事 会 , M . WANG H 董 事 会 董 事 会
C 董 事 会 M . JIN H 董 事 会 董 事 会 C 董 事 会 董 事 会 J 董 事 会 10, 2022.

O J 董 事 会 17, 2022, 董 事 会 董 事 会 , M . CHEN J 董 事 会 董 事 会
S 董 事 会 C 董 事 会

O F 董 事 会 15, 2022, 董 事 会 董 事 会 董 事 会 董 事 会 董 事 会 董 事 会
, M . SUN F 董 事 会 董 事 会 S 董 事 会 C 董 事 会 董 事 会 董 事 会
S 董 事 会 .

O F 董 事 会 19, 2022, 董 事 会 董 事 会 董 事 会 董 事 会 董 事 会 董 事 会 C 董 事 会 M . XUN
董 事 会 董 事 会 董 事 会 S 董 事 会 , 董 事 会 董 事 会 董 事 会 董 事 会
S 董 事 会 C 董 事 会 C 董 事 会

O J 董 事 会 12, 2022, M . NG W S 董 事 会 董 事 会 董 事 会 董 事 会 C 董 事 会 (董 事 会 C
, A 董 事 会 R 董 事 会 董 事 会 董 事 会 董 事 会 董 事 会 董 事 会
董 事 会 4T) C 董 事 会 H KH 董 事 会 4T T 0 董 事 会 16 C 董 事 会 DO 董 事 会 622 C 董 事 会 L 董 事 会 D KH

Corporate Governance Report

I. C P D D

D R P , C . A B D ,
H K L R . T
B - . T D
:

D R P , D C M . GUAN W , M . WANG L , M . WANG H (S 1, 2022), M . QIN H , M . LI C , M . ZHAO X (M 10, 2023), M . ZHONG W M . LIU N , D ,

C M C

A.3 M C , 30
() ,
(B - P). B.8 M
C
:

T C J 30, 2022 (I)
J 10, 2023. I D 28, 2022, C D ,
S C , ()
I R ; () D C S
C B - P (. D 11, 2022 J 10, 2023).

O J 5, 2023, C M . WANG L (M .) , D ,
M . W 100,000 S C M .
W J , C RMB13.28 S D 19, 2022 (D) . P D , M . W / B D
C A M . W S C B - P
C D C M . W
A.3 B.8 M C .

Corporate Governance Report

T C , S , M C :

- (1) M . W D (M . W) C B ;
- (2) D , S M C C C
- (3) D , S C

T B C B - P C T C M C D , S

T C , S B - P . T C C S , C , C . I

S S , C M C C D S , D S M C R P .

Corporate Governance Report

C O R P O R A T E G O V E R N A N C E

On March 10, 2023, the Board of Directors of Wenzhou Kangning Hospital Co., Ltd. (the "Company") held a meeting to discuss and approve the 2022 Annual Report of the Company. The meeting was attended by Mr. M. ZHAO X, Chairman of the Board, and Mr. M. ZHAO X, Chairman of the Board of Supervisors. The meeting was held in accordance with the provisions of the Company's Articles of Association and the Regulations for the Board of Directors. The meeting discussed and approved the 2022 Annual Report of the Company, including the financial statements, the Board's report, and the Board of Supervisors' report. The meeting also discussed and approved the 2022 Annual Report of the Company's subsidiaries. The meeting was held in accordance with the provisions of the Company's Articles of Association and the Regulations for the Board of Directors. The meeting discussed and approved the 2022 Annual Report of the Company, including the financial statements, the Board's report, and the Board of Supervisors' report. The meeting also discussed and approved the 2022 Annual Report of the Company's subsidiaries.

The Board of Directors of the Company is composed of 11 members, including 3 independent non-executive directors. The Board of Supervisors of the Company is composed of 3 members, including 1 independent non-executive director. The Company has established a complete corporate governance structure, including the Board of Directors, the Board of Supervisors, the Management, and the Shareholders.

S T R U C T U R E O F C O R P O R A T E G O V E R N A N C E

The Company's corporate governance structure is shown in the following diagram. The Shareholders elect the Board of Directors and the Board of Supervisors. The Board of Directors is responsible for the overall management of the Company, while the Board of Supervisors is responsible for supervising the Board of Directors and the Management. The Management is responsible for the day-to-day operations of the Company. The Company also has a Shareholders' Meeting, which is the highest decision-making body of the Company.

A S S E S S M E N T O F C O R P O R A T E G O V E R N A N C E

The Company's corporate governance structure is sound and effective. The Board of Directors and the Board of Supervisors are independent and objective. The Management is professional and experienced. The Company has established a complete system of internal control and risk management. The Company's corporate governance structure has been continuously improved and strengthened.

A D D I T I O N A L I N F O R M A T I O N

The Company's corporate governance structure is shown in the following diagram. The Shareholders elect the Board of Directors and the Board of Supervisors. The Board of Directors is responsible for the overall management of the Company, while the Board of Supervisors is responsible for supervising the Board of Directors and the Management. The Management is responsible for the day-to-day operations of the Company. The Company also has a Shareholders' Meeting, which is the highest decision-making body of the Company.

The Company's corporate governance structure is shown in the following diagram. The Shareholders elect the Board of Directors and the Board of Supervisors. The Board of Directors is responsible for the overall management of the Company, while the Board of Supervisors is responsible for supervising the Board of Directors and the Management. The Management is responsible for the day-to-day operations of the Company. The Company also has a Shareholders' Meeting, which is the highest decision-making body of the Company.

Corporate Governance Report

<p>C T A T C D</p>	<p>Annual Report N III (XXXI) F S - S B M G M C.5.1 CG C .N D 11 B D B</p>	<p>11/11 11/11 5/5 11/11 11/11 11/11 11/11 11/11</p>
<p>E D M . GUAN W (C) M . WANG L M . WANG H (S 1, 2022)</p>	<p>11 B D B</p>	<p>11/11 11/11 5/5</p>
<p>N - D M . QIN H M . LI C</p>	<p>11 B D B</p>	<p>11/11 11/11</p>
<p>I - D M . ZHAO X (M 10, 2023) M . ZHONG W M . LIU N</p>	<p>11 B D B</p>	<p>11/11 11/11 11/11</p>

A D
M
B
B
B
T

B
D
D
D
B
D

Corporate Governance Report

Director	Term of Office	Resignation
Executive Director		
M. GUAN W (Chairman)		1/1
M. WANG L		1/1
M. WANG H (Independent Director)	Since 1, 2022	0/0
Non-Executive Director		
M. QIN H		1/1
M. LI C		1/1
Independent Director		
M. ZHAO X (Independent Director)	Since 10, 2023	1/1
M. ZHONG W		1/1
M. LIU N		1/1

Corporate Governance Report

B 董事

本公司董事会由 7 名董事组成，包括 3 名独立董事和 4 名非独立董事。董事会成员包括：董事长 王 ()、副董事长 李 ()、董事 张 ()、董事 陈 ()、董事 周 ()、董事 吴 ()、董事 郑 ()。所有董事均持有公司股份，且均为中国公民。所有董事均持有公司股份，且均为中国公民。

A 高级管理人员

本公司高级管理人员包括：总经理 李 ()、副总经理 张 ()、财务总监 王 ()、董事会秘书 陈 ()。所有高级管理人员均持有公司股份，且均为中国公民。所有高级管理人员均持有公司股份，且均为中国公民。

本公司高级管理人员，包括：总经理 李 ()、副总经理 张 ()、财务总监 王 ()、董事会秘书 陈 ()。所有高级管理人员均持有公司股份，且均为中国公民。所有高级管理人员均持有公司股份，且均为中国公民。

本公司高级管理人员，包括：总经理 李 ()、副总经理 张 ()、财务总监 王 ()、董事会秘书 陈 ()。所有高级管理人员均持有公司股份，且均为中国公民。所有高级管理人员均持有公司股份，且均为中国公民。

D /

M . ZHONG W ()	5/5
M . LIU N	5/5
M . LI C	5/5

Corporate Governance Report

NEC

TC (CGC) NEC
D, NEC
B, C, D
C, D
B, D
D
B, D
B, D
B

A, D, NEC
() B, B
() .N NEC
B, T
() C

A, NEC
(NEC), D, M. GUAN W. T
C R P, B
- D B

T D NEC R P

D	/
M. LIUN (C)	2/2
M. GUAN W	2/2
M. ZHAO X (M 10, 2023)	2/2

T B C G R -B D P . P

Corporate Governance Report

R C

T C R C CGC
R C R C B . T D
D
D
D
;
/ D C 17 H K L R ;
D C
B .

A , R C - D , M .
ZHONG W M . LIU N . T R C
E.1.2() CGC (. . B
D () . O R C R P ,
C 2021.

T D R C R P
:

D	/
M . ZHAO X (C) (M 10, 2023)	1/1
M . ZHONG W	1/1
M . LIU N	1/1

T G ' D C
D / . T -
D D ,
B .

T D D 31, 2022 N F S -
R

Corporate Governance Report

S R C
T C S R M C

Corporate Governance Report

C	C	B	G	D
A				
30-49	(3)		F (33.3%)	1-5 (4)
50-59	(3)		M (66.7%)	6-10 (2)

T B 2 D 4 D . T B C B . T N C B , D 31, 2022, B

G D W
A D 31, 2022, G 4,196 (), 66.63%
33.37% . T G R M M
《招錄管理辦法》. D , G ,

C G F
T B , :
(a) C CG C ;
() C ;
() , D ;
() D , S ;
() C

D R P , B , : (1) D , S ; (2) D ; (3) ; (4)

Corporate Governance Report

Director's Report

On December 31, 2022, the Board of Directors of Wenzhou Kangning Hospital Co., Ltd. (the "Company") has completed its work for the year. The Board has reviewed the Company's financial statements and business performance for the year, and has approved the following resolutions:

1. To approve the Company's financial statements for the year 2022.

2. To approve the Company's business performance report for the year 2022.

3. To approve the Company's dividend distribution plan for the year 2022.

The Board of Directors has also reviewed the Company's internal control system and risk management system, and has approved the following resolutions:

1. To approve the Company's internal control system and risk management system for the year 2022.

2. To approve the Company's internal control system and risk management system for the year 2022.

Management Report

The Management of Wenzhou Kangning Hospital Co., Ltd. has completed its work for the year. The Management has reviewed the Company's financial statements and business performance for the year, and has approved the following resolutions:

1. To approve the Company's financial statements for the year 2022.

2. To approve the Company's business performance report for the year 2022.

The Management has also reviewed the Company's internal control system and risk management system, and has approved the following resolutions:

1. To approve the Company's internal control system and risk management system for the year 2022.

2. To approve the Company's internal control system and risk management system for the year 2022.



WENZHOU KANGNING HOSPITAL CO., LTD.
2022 ANNUAL REPORT

Corporate Governance Report

Shareholder Structure

Table 1: Shareholder Structure as of December 31, 2022

(MB)

0-700,000	1
700,001-1,400,000	6

Annual Report

For the period ending December 31, 2022, the Group, BDO, PricewaterhouseCoopers (PwC) and Deloitte Touche Tohmatsu Limited (DTTL) have audited the financial statements of the Company for the year ended December 31, 2022, and issued an unqualified audit opinion.

The annual report is available on the company's website at www.wenzhoukangninghospital.com in Chinese and English. RMB5,300,000

The annual report is available on the company's website at www.wenzhoukangninghospital.com in Chinese and English. RMB1,066,300

Joint Shareholders

Director Mr. M. WONG Wai C and Mr. M. WANG Jia, Chairman Mr. M. WONG Wai C and Mr. M. WANG Jia, Secretary Mr. M. WONG Wai C and Mr. M. WANG Jia, and Treasurer Mr. M. WONG Wai C and Mr. M. WANG Jia.

Director Mr. M. WONG Wai C and Mr. M. WANG Jia, Chairman Mr. M. WONG Wai C and Mr. M. WANG Jia, Secretary Mr. M. WONG Wai C and Mr. M. WANG Jia, and Treasurer Mr. M. WONG Wai C and Mr. M. WANG Jia.

On July 12, 2022, Mr. NG Wai S and Mr. M. WONG Wai C, Mr. M. WANG Jia, SWCS C and S G (H K) L, and Mr. M. WONG Wai C.

Corporate Governance Report

C O R P O R A T E S T A K E H O L D I N G S

At the end of the reporting period, the company's shares were held by 10,000 shareholders, including 10,000 natural persons, 10,000 legal persons, and 10,000 trusts. The company's shares were listed on the Shanghai Stock Exchange.

The company's shares were held by 10,000 shareholders, including 10,000 natural persons, 10,000 legal persons, and 10,000 trusts. The company's shares were listed on the Shanghai Stock Exchange.

The company's shares were held by 10,000 shareholders, including 10,000 natural persons, 10,000 legal persons, and 10,000 trusts. The company's shares were listed on the Shanghai Stock Exchange.

The company's shares were held by 10,000 shareholders, including 10,000 natural persons, 10,000 legal persons, and 10,000 trusts. The company's shares were listed on the Shanghai Stock Exchange.

The company's shares were held by 10,000 shareholders, including 10,000 natural persons, 10,000 legal persons, and 10,000 trusts. The company's shares were listed on the Shanghai Stock Exchange.

S H A R E H O L D I N G S

At the end of the reporting period, the company's shares were held by 10,000 shareholders, including 10,000 natural persons, 10,000 legal persons, and 10,000 trusts. The company's shares were listed on the Shanghai Stock Exchange.

The company's shares were held by 10,000 shareholders, including 10,000 natural persons, 10,000 legal persons, and 10,000 trusts. The company's shares were listed on the Shanghai Stock Exchange.

The company's shares were held by 10,000 shareholders, including 10,000 natural persons, 10,000 legal persons, and 10,000 trusts. The company's shares were listed on the Shanghai Stock Exchange.

The company's shares were held by 10,000 shareholders, including 10,000 natural persons, 10,000 legal persons, and 10,000 trusts. The company's shares were listed on the Shanghai Stock Exchange.

Corporate Governance Report

I S V C EGM ,

I S V C EGM
S V C
10% S 90 S EGM
N S C S

P S () P F P G M
W C B , S C S

S 3% S 3% S
10 EGM. T
2 . T

A :
N .1 S R
H R D
W , Z
PRC
Tel: (86) 577 8878 9117
E : @

P D 'E B
S B B
T :

A :
N .1 S R
H R D
W , Z
PRC
Tel: (86) 577 8878 9117
E : @

S B C

Corporate Governance Report

C C D

D R P , A .

D P

T C W C -
 , 10% C C . T C 50%
 C . S C
 C C ,
 C - , . A
 , . A C S
 S S A
 S C N S

T C ():

- (I) ;
- (II) ;
- (III) , , , , , .

T C RMB S . S
 C S RMB HKD. S HKD
 C S .

T B C

Directors, Supervisors and Senior Management

D

E D

M . G A N (管偉立), 53, B D . H
C H C F 1996

Directors, Supervisors and Senior Management

NON-EXECUTIVE DIRECTORS

M. QIN H (秦浩), 32, Male, Bachelor's Degree, G J 2021. H (上海正心谷投資管理有限公司), S L V I M C , L J 2017 D 2021.

M. Q P U J 2014 . H F U J 2017 .

M. LI C (李昌浩), 33, Male, Bachelor's Degree, G O 2021. H SDIC C I F M C , L . (國投創益產業基金管理有限公) J 2022, . H SDIC C I F M C , L . M 2014 D 2021. H Y A C , L . (雲南鋁業股份有限公司), S S

Directors, Supervisors and Senior Management

INDEPENDENT

M. HONG (鐘文堂), 33, Male, Bachelor's Degree, Accountant, J 2020. S (上海信公企業管理諮詢有限公司), F 2019, F 2016 F 2019, M. Z I C C., L., F O 2012 F 2016, C Z T CPA L

M. Z Male, Bachelor's Degree, Accountant, J 2012. S M B A F U J 2022.

M. LI (劉寧), 59, Male, Bachelor's Degree, J 2020. H W H T G C., L. (: 300253.SZ) A 2004, S F 2018, K M T (S) C., L. (快享醫療科技(上海)有限公司), S J 2018, B W H T C., L. (北京衛寧健康科技有限公司), S O 2019, S W T C., L. (上海衛心科技有限公司), F A 1991 A 2004, U S H - (HP) C (上海金仕達衛寧醫療信息技術有限公司).

M. L Male, Bachelor's Degree, J 1985, F U S J 1988, H S H - A T E S (上海市工程系列高新技術成果轉化類高級專業技術職務任職資格評審委員會) M, 2000.

S

M. (許寧), 49, Male, Bachelor's Degree, J 2016, M. X C H M 2016, C M. X M 2016 O 2016, F N 2016 D 2017, H C J 2018 J 2022. H J 2022. H M 2023. P C W TV S (溫州電視台) (溫州新聞聯播), W N S 1998 F 2016,

Directors, Supervisors and Senior Management

M. XIAO (肖) B. B. I. (北京廣播學院) (中國傳媒大學) J. 1998 (一級人力資源管理師) M. H. R. S. S. P. R. C. F. 2018.

M. (徐永久), 45, S. H. C. O. 2021, S. A. 2023, S. J. J. E. I. Ma. C., L. (上海金浦健服股權投資管理有限公司) S. J. 2021, W. J. E. I. Pa. (L. Pa.) (溫州金寧股權投資合夥企業(有限合夥)). S. J. 19, 2018, C. Y. H. C., L. (成都怡寧醫院有限公司). S. F. 2016, S. Y. I. C., L. (上海銀驛投資有限公司). F. J. 2004 D. 2007, D. R. H. S. I. G. . F. D. 2007 Ma. 2009, I. B. H. A. Pa. C. . F. Ma. 2009 S. 2011, S. I. G. S. I. H. S. T. . F. O. 2011 O. 2015, M. X. GP Co. C., L. (金浦產業投資基金管理有限公司). F. A. 2016 Ma. 2023, S. J. J. E. I. Ma. C., L. (上海金浦健服股權投資管理有限公司).

M. X. S. U. F. E. J. 2000. H. F. U. J. 2004. S. J. 2015, S. L. S. F. U. H. C. E. I. B. S. EMBA (E. Ma. B. A.) N. 2022.

M. QIAN C (錢成良), 72, S. H. M. Q. C. J. 2017 S. P. C. Ma. 2007 Ma. 2012, S. S. U. 8.15

Directors, Supervisors and Senior Management

S M

M. HO C (周朝毅), 60, . H C M. Z C F 2005 . H S 2014 C N 1995 D 2004, M. Z W C H (温州心血管醫院) . F M, 1990 O 1995, M. Z (

Directors, Supervisors and Senior Management

M. (徐誼), 48, C. M. X. O. 2002
 (科長) O. 2002 Mar. 2009,
 . F A 2009 S 2014, C H
 S 2014 C P

Directors, Supervisors and Senior Management

M J INH (金輝), 36, . H . P C
 H C 2022 . P C
 L (浙江華明會計師事務所有限公司) F 2012 D 2021, . H
 W ; - ; ,
 M P ' C N 2018, . H W
 . P Z H C P A C L ,
 W L C P A C L (溫州立德會計師事務所有限公司)

Directors, Supervisors and Senior Management

D M	/	M	G	P M	H G	O
WANG L		Y Ka	H	Es		F Ja 2017
		Ma	C.,L.	Ma		
		Q	Ka H	Ma		F D 2018
		C.,L.				
		B	Y H	D		F Ma 2019
		C.,L.				
		H	Y N	Es		F D 2020
		S	C.,L.	G		
		Z	F	D		F F 2022
		N	T			
		C.,L.				
		Z	Y H	Es		F S 2022
		T	C.,L.			
		Z	D	C		F S 2022
		P	C.,L.			
		C	Ka	D		F N 2022
		H				
		H	C.,L.			

Directors, Supervisors and Senior Management

D M	/	M	G	P M	H G	O
XU	Y	Q	K	H	S	F A 2011
		C.,L.				
		Y	K	H	S	F S 2013
		C.,L.				
		S	Y	H	S	F S 2014
		C.,L.				
		W	Y	G	S	F N 2015
		H	C.,L.			
		B	Y	H	S	F A 2015
		C.,L.				
		S	Y	M	S	F S 2015
		I	C.,L.			
		Q	Y	H	S	F N 2015
		C.,L.				N 2022
		Z	H	H	C	F A 2016
		M	C.,L.			
		T	K	H	E	F J 2016
		C.,L.				
		Z	K	H	E	F J 2016
		M	(G)	G		
		C.,L.				
		H	Y	H	C	F A 2017 A 2022
		C.,L.				
		T	L	C	E	F D 2016
		H	C.,L.	M		
		H	K	H	C	F J 2018
		C.,L.				
		H	C	H	E	F N 2017
		C.,L.			G	
		W	T	TCM	E	F J 2018
		C	C.,L.			
		W	T	TCM	G	F J 2018
		C	C.,L.			A 2022
		Z	J	H	E	F D 2018
		T	C.,L.		G	
		W	L	Y	D	F A 2020
		H	C.,L.			
		W	J	J	E	F D 2021
		T	C.,L.		G	
		W	Y	H	D	F A 2022
		T	C.,L.			

Directors, Supervisors and Senior Management

D / P H
M M G .

Directors, Supervisors and Senior Management

D M	/	M	G	P M	H G	O
ZHANG F	张	L C.,L.	K H C.,L.	E M	, M	F J 2018
		W S L C.,L.	N P H C.,L.	D		F J 2019
		L C.,L.	C H C.,L.	E M	, M	F D 2020
YE M	叶	W T	Y H C.,L.	E G	, M	F M 2019 J 2022
JIN W	金	Q C.,L.	Y H C.,L.	D		F N 2015 N 2022
		H P H C.,L.	Y P H C.,L.	D		F D 2018
		P H C.,L.	C Y H C.,L.	E M	, M	F S 2021
		G C C.,L.	Y N C C.,L.	E G	, M	F M 2021 D 2022
XUN	徐	G C.,L.	Y H C.,L.	E M	, M	F J 2019
		H P H C.,L.	Y P H C.,L.	C		F M 2020
JIN H	金	W E C.,L.	O Y H C.,L.	S		F S 2022
		G C C.,L.	Y N C C.,L.	S		F S 2022

A

III. K A Ma

K A Ma . T

A ,

	A M	H
1.	D , , ()	, , , , , , , , , ,



A ’

A ,

IV. O I

Ma Ka H (Ma)
. T 2022 Ka
H . Ka H ' 2022

O
.

I ,
, , ,
.

W Ka H ' 2022 A R ,
,
.

V. R Ma T C G
F S

T Ma
CAS ,
,

I , W Ka H '
, , ,
Ma W Ka H

T W Ka H ' .

A ,

VI. A

C		B						
A 31 D 2022		RMB Y		()				
				D	31,	D	31,	J 31,
LIABILITY AND		N V		2022	2021	2021		
HOLDERS' EQUITY				(R)		(R)		
C :								
S	-	(XIX)		203,000,000.00	254,050,000.00	312,500,000.00		
B								

A E	N XVI	D 31, 2022	D 31, 2021	Jūnija 30, 2021
			(RUB)	(RUB)

P R O F I T A N D L O S S S T A T E M E N T

A T D E C E M B E R 31, 2022
(A M O U N T I N R M B Y E A R)

LIABILITIES AND EQUITY	D E C E M B E R 31, 2022	D E C E M B E R 31, 2021	J A N U A R Y 1, 2021
附 属 公 司 持 有 者 权 益	(R M B)	(R M B)	(R M B)
C O N C E R N E D P A R T I E S :			
S H A R E H O L D E R S E Q U I T Y	195,000,000.00	251,050,000.00	310,000,000.00
F O R E I G N I N V E S T M E N T			
D O M E S T I C I N V E S T M E N T			
N O N - C O N T R O L L I N G S H A R E H O L D E R S	20,689,401.73	13,161,555.37	34,954,083.13
M A J O R I T Y S H A R E H O L D E R S	3,299,924.90	2,011,708.12	
C O N T R O L L I N G S H A R E H O L D E R S			3,480,241.45
E X T R A - R E T A I N E D E A R N I N G S	18,740,841.95	17,876,433.39	15,629,765.62
T R A N S L A T E D F O R E I G N C U R R E N C Y	597,972.12	4,848,233.63	8,267,930.79
O T H E R R E S E R V E S	49,473,505.95	74,941,835.88	27,298,927.14
L O A N F O R G A I N E X C H A N G E			
N O N - C O N T R O L L I N G I N T E R I M D I V I D E N D S	91,487,500.00	3,000,000.00	
O T H E R S			
	379,289,146.65	366,889,766.39	399,630,948.13
N O N - C O N T R O L L I N G I N T E R I M D I V I D E N D S :			
L O A N F O R G A I N E X C H A N G E	284,750,000.00	200,950,000.00	38,000,000.00
B O N D			
I N T E R I M D I V I D E N D S			
P A Y A B L E I N T E R I M D I V I D E N D S			
L O A N F O R G A I N E X C H A N G E			
L O A N F O R G A I N E X C H A N G E	25,922,687.47		
L O A N F O R G A I N E X C H A N G E			
P R O V I D E N T F O R U N E M P L O Y E E B E N E F I T P L A N			
D E B T F O R I N T E R I M D I V I D E N D S	9,037,891.00	9,341,683.00	9,645,475.00
D E B T F O R I N T E R I M D I V I D E N D S	2,291,279.89	2,853,156.89	1,607,648.32
O T H E R S			

LIABILITY AND HOLDERS' EQUITY	December 31, 2022	December 31, 2021	January 1, 2021
(RMB)	(RMB)	(RMB)	(RMB)
Share Capital	74,600,300.00	74,600,300.00	74,600,300.00
Other Reserves			
Capital Reserve	871,230,628.64	854,317,490.93	834,138,174.86
Surplus Reserve	38,399,577.13	38,399,577.13	36,593,228.71
Minority Interest	241,903,691.18	214,974,182.62	198,717,046.87
	1,226,134,196.95	1,182,291,550.68	1,120,737,606.60
Total Liability and Holders' Equity	1,927,425,201.96	1,762,326,156.96	1,569,621,678.05

Total assets equals total liability and holders' equity.

Liability and holders' equity prepared by: PricewaterhouseCoopers : Head of member firm :
GUAN W JIN H WANG M

C O N T E N T S

2022

(A R M B Y)

I	N	V	A	A
				(R)
I.			1,484,903,042.25	1,297,430,369.83
I	: R	(XXXVII)	1,484,903,042.25	1,297,430,369.83
	I			
	P			
	F			
II.			1,435,161,133.62	1,226,514,555.85
I	: C	(XXXVII)	1,131,971,942.77	968,432,455.76
	I			
	F			
	S			
	N			
	N			
	I			
	R			
	T	(XXXVIII)	4,960,285.79	5,754,219.28
	S	(XXXIX)	15,004,027.73	10,335,392.65
	G	(XL)	205,887,172.40	176,371,888.82
	R	(XLI)	33,027,987.79	27,962,173.39
	F	(XLII)	44,309,717.14	37,658,425.95
	I		45,149,998.30	36,267,756.91
	I		2,761,765.05	1,691,366.88
A	: O	(XLIII)	14,907,710.81	13,619,635.06
	I	(XLIV)	2,850,458.27	6,937,845.27
	I			
	D		-15,926,847.45	-6,565,719.92
	F			
	G			
	G			
	C	(XLV)	-15,977,325.91	9,417,390.73
	A	(XLVI)	-25,191,541.19	-2,140,196.45
	A	(XLVII)	-10,345,460.56	-6,179,290.37
	G	(XLVIII)	406,184.95	-79,403.55
III. O			16,391,935.00	92,491,794.67
A	: N	(XLIX)	8,553,977.86	11,835,931.80
L	: N	(L)	9,341,038.73	8,636,583.42
I.			15,604,874.13	95,691,143.05
L	: I	(LI)	26,573,712.49	54,830,913.00

C I
F 2022
(A RMB Y)

I N V A A
(R)

附 表
F 附 表
(A 附 表)
2022
RMB Y 附 表)

I	N	XVI	A	A
I.		(IV)	343,141,450.63	369,798,306.12
L : C		(IV)	265,024,147.50	271,489,388.70
T			154,333.60	3,013,304.93
S			1,692,773.94	3,068,742.71
G			82,345,368.26	70,825,757.20
R			18,899,109.47	16,486,961.41
F			16,480,521.45	5,650,976.01
I : I			26,568,676.00	19,722,968.32
I			11,229,395.04	14,521,251.32
A : O			6,245,933.48	5,326,738.38
I	((V)	49,902,280.65	4,923,377.54
I : I			-5,377,605.11	-3,485,811.81
D				
G	(
-)			
G	(-2,695,422.53	8,407,356.31
-)			

附 录
F 录
(A 附 录
RMB Y 附 录)

I N XVI A A

- . O
- (I) O
- 1. C
- 2. O
- 3. C
- 4. C
- (II) O
- 1. O
- 2. C
- 3. A
- 4. C
- 5. R
- 6. E
- 7. O

I. 26,929,508.56 18,063,484.17

- II.E
- (I) B (RMB)
- (II) D (RMB)

T

L : P : H :
GUAN W JIN H WANG M

C
F 2022

C F

I N V A A

I. C						
G	▼	▲				
N	▲		▲	▲		1,452,028,763.13
N	▲		▲	▲		1,211,114,150.81
N	▲	▲		▲	▲	

C		C		F	
F 2022					
(A RMB Y)					
I		N	V	A	A
II. C					
G				1,650,804.41	52,119,175.58
G					7,777,189.35
Z				24,100,366.61	8,755,311.37
Z					
G					
				25,751,171.02	68,651,676.30
G				236,910,178.88	178,536,614.68
G					48,600,000.00
Z				53,685,701.28	80,564,032.90
Z				8,770,704.43	
G		(LIV)			
				299,366,584.59	307,700,647.58
Z				-273,615,413.57	-239,048,971.28
III. C					
G				9,153,084.38	2,900,000.00
I					
				9,153,084.38	2,900,000.00
G				387,500,000.00	550,250,000.00
G				151,420,250.00	
			(LIV)		
				548,073,334.38	553,150,000.00
G				324,220,000.00	428,342,970.00
G					
				51,554,507.56	30,297,107.09
I					
G				56,121,295.37	60,676,565.61
			(LIV)		
				431,895,802.93	519,316,642.70
Z				116,177,531.45	33,833,357.30
I . E					
				78,462.87	-38,704.15
Z				69,861,145.20	-11,357,819.65
A : C				188,734,845.77	200,092,665.42
I. C				258,595,990.97	188,734,845.77
			(LV)		
			(LV)		
T					
L					
GUAN W					
P					
JIN H					
H					
WANG M					

附 表
P
F
(A
C
2022
RMB Y
C
F
)

I	N	A	A
I. C			
G		336,363,866.37	367,674,455.38
R			
G		495,591,067.36	804,490,679.80
-		831,954,933.73	1,172,165,135.18
G		153,275,777.22	176,137,498.58
G		147,419,578.70	141,102,134.39
P		2,393,183.16	9,767,527.34
G		596,762,811.79	710,127,325.96
-		899,851,350.87	1,037,134,486.27
N		-67,896,417.14	135,030,648.91
II. C			
G		12,396,717.38	
G		2,298,348.18	7,089,189.35
N			
G		32,054.56	37,820.00
N			
G			
-		14,727,120.12	7,127,009.35
G		14,643,564.50	37,662,933.95
G		54,309,855.16	212,313,500.00
N			
G			
-		68,953,419.66	249,976,433.95
N		-54,226,299.54	-242,849,424.60

附 表
P
F
(A
2022
RMB Y)

I	N	A	A
III. C			
Gr		334,500,000.00	518,050,000.00
Gr		120,000,000.00	
		454,500,000.00	518,050,000.00
Gr		306,750,000.00	411,050,000.00
Gr		26,512,297.06	19,663,754.20
Gr		6,421,875.00	
		339,684,172.06	430,713,754.20
N		114,815,827.94	87,336,245.80
I . E		78,462.87	-38,704.15
. N		-7,228,425.87	-20,521,234.04
A : Gr		97,615,570.76	118,136,804.80
I. C		90,387,144.89	97,615,570.76

T

L : P : H :
GUAN W JIN H WANG M

		2022		2021	
		RMB Y		RMB Y	
		A		B	
		E		F	
		O		N	
		P		P	
		L		L	
		C		C	
		O		O	
		P		P	
		O		O	
I					
I. B		74,600,300.00			
P : C			888,165,395.59	38,899,577.13	257,098,624.31
C					1,208,263,897.03
B					72,015,223.54
O					1,280,279,120.57
II. B		74,600,300.00	888,165,395.59	38,899,577.13	257,098,624.31
III. I /					
()					
(I) T		16,913,137.71		-23,592,089.88	-6,678,952.17
(II) O				-24,220,782.31	-24,220,782.31
I. C		12,214,418.85			12,214,418.85
2. C					43,363,506.48
3. A					43,363,506.48
4. O					
(III) D					
1. W					
2. W					
3. P					
4. O					

附 表 1
2022 年
资产负债表

项 目	2022 年 12 月 31 日	2021 年 12 月 31 日
项 目	人民币元	人民币元
流动资产	1,201,584,944.86	1,243,876,731.97
非流动资产	1,201,584,944.86	1,243,876,731.97
资产总计	2,403,169,889.72	2,487,753,463.94
流动负债	628,692.43	5,327,411.29
非流动负债	628,692.43	5,327,411.29
负债总计	1,231,861,535.30	1,248,738,842.58
所有者权益	1,171,308,354.42	1,239,014,621.36
股本	74,600,300.00	74,600,300.00
资本公积	855,078,533.30	855,078,533.30
盈余公积	38,999,577.13	38,999,577.13
未分配利润	233,506,534.43	233,506,534.43
所有者权益合计	1,171,308,354.42	1,239,014,621.36

(IV) 元

1. 流动资产

货币资金

应收账款

预付款项

其他应收款

存货

其他流动资产

2. 非流动资产

长期股权投资

固定资产

无形资产

其他非流动资产

3. 负债

应付账款

预收款项

其他应付款

其他流动负债

4. 所有者权益

股本

资本公积

盈余公积

未分配利润

6. 所有者权益

(V) 元

1. 流动资产

货币资金

应收账款

预付款项

其他应收款

存货

其他流动资产

2. 非流动资产

长期股权投资

固定资产

无形资产

其他非流动资产

3. 负债

应付账款

预收款项

其他应付款

其他流动负债

4. 所有者权益

股本

资本公积

盈余公积

未分配利润

(VI) 元

1. 流动资产

货币资金

应收账款

预付款项

其他应收款

存货

其他流动资产

2. 非流动资产

长期股权投资

固定资产

无形资产

其他非流动资产

3. 负债

应付账款

预收款项

其他应付款

其他流动负债

4. 所有者权益

股本

资本公积

盈余公积

未分配利润

附 表 C
2022 年度
现金流量表
(人民币元)

项 目	2022 年	2021 年
项 目	2022 年	2021 年
一、经营活动产生的现金流量		
1. 销售商品、提供劳务收到的现金	257,098,624.31	1,208,263,897.03
2. 收到的税费返还		
3. 收到其他与经营活动有关的现金	38,599,577.13	72,013,233.54
经营活动现金流入小计	295,698,201.44	1,280,277,130.57
1. 购买商品、接受劳务支付的现金	(1,526,420.61)	(23,311,143.84)
2. 支付给职工以及为职工支付的现金	(88,165,595.59)	
3. 支付的各项税费		
4. 支付其他与经营活动有关的现金	(21,784,723.23)	
经营活动现金流出小计	(90,471,740.43)	(23,311,143.84)
经营活动产生的现金流量净额	205,226,461.01	1,256,965,986.73
二、投资活动产生的现金流量		
1. 收回投资收到的现金		
2. 取得投资收益收到的现金		
3. 处置固定资产、无形资产和其他长期资产收回的现金净额		
4. 处置子公司及其他营业单位收到的现金净额		
5. 收到其他与投资活动有关的现金		
投资活动现金流入小计		
1. 购建固定资产、无形资产和其他长期资产支付的现金		
2. 投资支付的现金		
3. 支付其他与投资活动有关的现金		
投资活动现金流出小计		
投资活动产生的现金流量净额		
三、筹资活动产生的现金流量		
1. 吸收投资收到的现金		
2. 取得借款收到的现金		
3. 收到其他与筹资活动有关的现金		
筹资活动现金流入小计		
1. 偿还债务支付的现金		
2. 支付其他与筹资活动有关的现金		
筹资活动现金流出小计		
筹资活动产生的现金流量净额		
四、汇率变动对现金及现金等价物的影响		
五、现金及现金等价物净增加额	205,226,461.01	1,256,965,986.73
六、期初现金及现金等价物余额	74,600,500.00	
七、期末现金及现金等价物余额	279,826,961.01	1,256,965,986.73

编制人：王 王
审核人：王 王

C O R P O R A T I O N ' S

F Y 2022
(A RMB Y)

A	L
0	0
P	L
P	L
0	0

F
(A 2022
RMB Y)

C O ' E

	0	A	O	S	S	R	T
	P P O	Ch T L :	S	S	R	T	T
	S P P O	Ch T L :	S	S	R	T	T
I. B P : C O	74,600,500.00	834,138,174.86	23,311,143.84	36,593,228.71	193,286,602.86	1,115,307,162.39	
					5,430,444.01	5,430,444.01	
II. B	74,600,500.00	834,138,174.86	23,311,143.84	36,593,228.71	198,717,046.87	1,120,737,606.60	
III. I /							
(I) T		20,179,316.07	-23,311,143.84	1,806,348.42	16,257,135.75	61,533,944.08	
(II) O		20,182,750.66			18,063,484.17	18,063,484.17	
1. C		2,445,056.34			20,182,750.66	20,182,750.66	
2. Ch						2,445,056.34	
3. A							
4. O		17,737,694.32				17,737,694.32	
(III) D							
1. W					1,806,348.42	-1,806,348.42	
2. P					1,806,348.42	-1,806,348.42	
3. O							
(IV) I							
1. C							
2. C							
3. S							
4. Ch							
5. Ch							
6. O							
(V) S							
1. W							
2. U							
(VI) O		-3,484.59	-23,311,143.84			23,307,709.25	
I. B	74,600,500.00	834,317,490.93	-23,311,143.84	38,399,577.13	214,974,182.62	1,182,291,350.68	
T							
L							
GUAN W							
JIN H							
WANG M							

T :
L :
GUAN W :
JIN H :
WANG M :

附 錄
F
F
(A 附 錄 2022
RMB Y 附 錄)

I. G 附 錄 附 錄

(I) C

W 附 錄 K 附 錄 H 附 錄 C ., L . (C 附 錄) 附 錄 附 錄 附 錄
附 錄 W 附 錄 C 附 錄 K 附 錄 P 附 錄 R 附 錄 附 錄 H 附 錄 (溫州市康寧精神康復醫院)
PRC F 附 錄 1996. T 附 錄 C 附 錄

N F
F 2022
(A RMB Y)

II. B

(I) B

T A S B E -
B S A S
B E , A S B E
M F (A S
B E). I ,
R G L S T S E H K L
H K C O .

(II) G

T .

III. S

1. T C
2. F , C ,
3. T C , R P . T C

N F
F 2022
(A RMB Y)

III. S ()

(I) A B E

T A S B E
M F , D 31, 2022 2022.

(II) A

T C 1 J 31 D .

(III) O

T C 12 .

(I)

T C R (RMB) T C
C PRC RMB. T . A
RMB.

() A

B : T ,
() T
() . I

附
F
F
(A
2022
RMB Y)

III. S ()

() A

()

B : T
W
C ;
T ,
T

T ;
T

(I) P

1. S
T

附 表

附 表 2022
(A 类) RMB Y ()

III. S ()

(I) P ()

2. C ()

T ,
- ,
- . I
- ,
- ,

(1) I

D R P , C ,

R P ;
- ;
- .

W , ,
- ,
- ,
- .

D R P , C ,
- ,
- .



 F 2022
 (A RMB Y)

III. S ()

(I) P ()

2. C ()

(1) I ()

W C ,
 -
 . W
 ,

(2) D

G

W C ,
 C . T
 . O



N **F**
F 2022
(A RMB Y)



N **F**
F 2022
(A RMB Y)

	2022	
F	RMB Y	
(A	Y)
III. S		()
() F		()
1. C		()

N **F**
F 2022
(A RMB Y)

N **F**
F 2022
(A RMB Y)

III. S ()

() F ()

2. R ()

(3) F ()

F ()
T
T

A ,

N **F**
F 2022
(A RMB Y)
III. S ()

附
F
(A 2022
RMB Y)

III. S ()

() F ()

6. T ()

I
C ;
C 12-
.T

I
C
30 C
U

I , C

I - , C

F A S
B E N .14 - R (2017),
C

N **F**
F 2022
(A RMB Y)

N F
F 2022
(A RMB Y)
III. S ()

(I)I

1. C
I
I . C
2. V
I
3. B
A . W
. N
N

N **F**
F 2022
(A RMB Y)

III. S ()

(I) I ()

- 4. I A
- 5. A T

(II) C

- 1. R T C
- 2. D F



	2022	
F	RMB Y)
III. S		()
(III) L	-	()
2. D		

N F
F 2022
(A RMB Y)

III. S ()

(III) L - ()

3. S

(1) L -

L - C
- - - . E
C

(2) L -

L - . W G
,
G , . W

T C
- . T
(O C O ' E)
,

T C , O C
O ' E
C

附 表 2022
(A) 人民币

III. S

(III) L

3. S

(2) L

U

T C

C

0.018

GS0

0.5

W

0.5

W

0.5

W

0.5

W

0.5

W

0.5

W

0.5

W

0.5

W

0.5

W

0.5

W

0.5

(8 T

N F
F 2022
(A RMB Y)

III. S ()

(I) B ()

4. M
F ,
 ,
 .

F ,
 ,
 .T
 .

D ,
 .T
 .

(II) I

1. V
(1) I ;
T ,
 .

(2) S
T C
A ,
 ;
 ,

附注
F
(A)

2022
RMB Y ()

III. S ()

(II) I ()

2. E

E

I	() A	B
L	40-50 S -	S
S	5 S -	E
C	20-30 S -	E
M	5-20 S -	E
T	10 S -	E

3. S
E
R : R
D : D

附 2022 年
财务报表附注
(A 股上市公司适用)

三、 重要会计政策及会计估计 (续)

(二) 收入

4. 合同收入 (续)

1. 收入确认原则

本公司在履行了合同中的履约义务，即在客户取得相关商品或服务控制权时确认收入。取得相关商品或服务控制权，是指能够主导该商品或服务的使用，并从中获得几乎全部的经济利益。

- (1) 销售商品收入
- (2) 提供劳务收入
- (3) 让渡资产使用权收入
- (4) 销售商品收入
- (5) 提供劳务收入

1. 销售商品收入

(三) 收入 (续)

1. 销售商品收入

2. 提供劳务收入

3. 让渡资产使用权收入

N F
F 2022
(A RMB Y)

III. S ()

(III) I ()

G , ,
 , ,
 .

W C , C ,
 , , .T
 .

F , ,
 , ,
 .T C
 ,
 .W
 ,
 -
 .

O ,

(I) L -

L -
 .

() C L

T C , T C
 .T C
 .C

N **F**
F 2022
(A RMB Y)

III. S ()

(I) E

1. A -
T -
W C
W C .N -

2. A -
(1) C
T C .D
.I , C
.T C /
.C

附 2022
F (A RMB Y)

III. S ()

(I) E ()

2. A - ()

(2) D
T C E A W U M .T

T
, .I , C

A ,

T .C .U ,

U ,

3. A
W C ,
(): C ;
C

附
F
F
(A
2022
RMB Y

III. S ()

(II) P

T C : ,

(1) C

(2) C

(3)

A

F

W

(3) W - () 0 T .5 ()0.5 ()0 3 9[.111 TD

N F
F 2022
(A RMB Y)

III. S ()

(III) -

A - C C
S - C
-

1. E -
T
F
F
C
-

I - C
I

I C
H

N F
F 2022
(A RMB Y)

III. S ()

(III) - ()

2. G - -)

A - - C F -
, , F - C
, F C

I C O ()
, C -
. A ,
. I

(I)

1. A

T C . C

I C

附 录
F
F
(A 附 录)
2022
RMB Y 附 录

III. S 附 录 ()

(I) ()

1. A ()
T C
T C
W
C
T C
W
C
T
W
C
O
C
A C
T C
G C
I
W
T C
W
C

附 表

附表 1 2022 年度
(A 股) 人民币元

III. 所有者权益

(一) 所有者权益

1. 实收资本 (人民币元)

本公司 2022 年度实收资本为人民币 100,000,000.00 元, 与 2021 年度实收资本一致。报告期内, 公司未发生增资扩股行为。

• 2022 年度, 公司未发生增资扩股行为, 实收资本为人民币 100,000,000.00 元。

N
F
(A 2022
RMB Y)

III. S ()

() C ()

I C ,

A ; , C .

F , C :

1. T ;

2. T .

I - , ,

(I) G

1. T

G - C

G C , G

2. T

G C

附 表 F
2022 年
人民币元

III. 所有者权益

(一) 股本

3. 股本

项目	2021 年 12 月 31 日	2022 年 12 月 31 日
股本	100,000,000.00	100,000,000.00
资本公积	100,000,000.00	100,000,000.00
盈余公积	100,000,000.00	100,000,000.00
未分配利润	100,000,000.00	100,000,000.00
所有者权益合计	400,000,000.00	400,000,000.00

(二) 其他权益工具

I. 优先股

项目	2021 年 12 月 31 日	2022 年 12 月 31 日
优先股	0.00	0.00

D. 其他

项目	2021 年 12 月 31 日	2022 年 12 月 31 日
其他	0.00	0.00

D. 其他

项目	2021 年 12 月 31 日	2022 年 12 月 31 日
其他	0.00	0.00

N
F
(A)

F
2022
RMB Y)

附
F
F
(A
2022
RMB Y

III. S ()

(III) L ()

1. T C

(1) R - -

A , C - -
(S -). R - -

-
- () ;
- C
- C ,

T C - . I
C , C ; ,
C

T C - -
N III. (XVIII) I -

N **F**
F 2022
(A RMB Y)

III. S ()

(III)L ()

1. T C ()

(2) L

A , C ()
-).L .L :

- (-), ()
);

- ;

- C

- C

- C .

T C C .I

T C ()
,)

Va ()
()

N
F 2022
(A RMB Y)

III. S ()

(III) L ()

1. T C ()

(2) L ()

A , C

A

附 表 2022
(A 类 人民币)

III. S ()

(III) L ()

1. T C ()

(4) L

T C :
:

- ;
-

I , C , - , .

I , C , F .

(5) R COVID-19

F COVID-19 , C , I . W , C .

附注
F
(A 附注) 2022
RMB Y 附注

III. S 附注 附注 附注 ()

(III) L ()

1. T C 附注 附注 ()

(5) R 附注 COVID-19 附注 ()

F - 附注 附注 附注 附注 , C 附注 附注 附注 附注 . I
附注 , C 附注 附注 附注 附注 ; 附注 附注
附注 , C 附注 附注 附注 附注 附注 附注 附注 附注
附注 附注 附注 附注 附注 附注 .

2. T C 附注 附注

A 附注 附注 附注 附注 , C 附注 附注 附注 附注 附注 附注
附注 . A 附注 附注 附注 附注 附注 附注 附注 附注 附注 附注
附注 附注 , 附注 ()0.5 ()0.366.5 (▼)0.5 ()0.5 ()0.5

N **F**
 F 2022
 (A RMB Y)
 III. S ()
 (III)

附 表 F

2022 年
人民币元

III. 重要事项

(三) 重要事项

2. 其他重要事项

(3) 新冠肺炎疫情

- 公司于2022年1月1日启动新冠肺炎疫情常态化防控工作，严格落实各项防控措施，保障员工和患者安全。公司根据《中华人民共和国传染病防治法》、《突发公共卫生事件应急条例》、《新型冠状病毒肺炎诊疗方案（试行第八版）》、《新型冠状病毒肺炎防控方案（第九版）》等法律法规和规范性文件的要求，结合公司实际情况，制定了《新冠肺炎疫情常态化防控工作预案》、《新冠肺炎疫情常态化防控工作实施细则》等制度，明确了各部门的职责分工和应急处置流程。公司定期开展疫情防控培训和应急演练，提高员工的防控意识和应急处置能力。同时，公司还加强了与卫生健康部门的沟通协作，及时获取最新的疫情信息和防控要求，确保防控工作科学有效。截至2022年12月31日，公司未发生新冠肺炎疫情。
- 公司于2022年1月1日启动新冠肺炎疫情常态化防控工作，严格落实各项防控措施，保障员工和患者安全。公司根据《中华人民共和国传染病防治法》、《突发公共卫生事件应急条例》、《新型冠状病毒肺炎诊疗方案（试行第八版）》、《新型冠状病毒肺炎防控方案（第九版）》等法律法规和规范性文件的要求，结合公司实际情况，制定了《新冠肺炎疫情常态化防控工作预案》、《新冠肺炎疫情常态化防控工作实施细则》等制度，明确了各部门的职责分工和应急处置流程。公司定期开展疫情防控培训和应急演练，提高员工的防控意识和应急处置能力。同时，公司还加强了与卫生健康部门的沟通协作，及时获取最新的疫情信息和防控要求，确保防控工作科学有效。截至2022年12月31日，公司未发生新冠肺炎疫情。

N F
F 2022
(A RMB Y)

III. S ()

(III) L ()

3. S ()

(2) T C

I - , C 2. T
C ; - ,
C , ,
F ,
N III(X)F .

(I)

T C ,

A C : (1)
; (2)
C ; (3)
C T

()

T C

1. E
A N III. (XXIV), C
T

附
F
(A 2022
RMB Y)

III. S ()
()

2. E
A N III. (XVIII), C
T
(N V. (XV))
I EBIT
EBIT
C
EBIT
C
3. E
T
C
()
C
4. M
I 2022, C
H Y H C., L
:

I	E	P
A ()		180
A (/)		570
N		10.79%
G (/)		60
D		14.00%
P		2.50%

IV. 非经常性损益
 F (A) 2022 RMB Y ()

III. S ()

(I) C

I 2021, M F N P D I E
 A S N . 15 I 2022 2023, M F N P
 D I E A S N . 16 Q&A I
 E A S . T C 31
 D 2022 Q&A. T C

IV. T

(I) M

V (VAT)	T VAT	3%, 6%, 13%
U B VAT	B VAT	7%
E B VAT	B VAT	5%
E B	B	15%, 20%, 25%
C		
I		
W K H C ., L .		15%
Z J H T C ., L .		15%
Y K H M C ., L .		20%

附 表
F
2022
(A RMB Y)

IV. T ()

(II) P

1. P C O P P P
L VAT P B T (C S [2016] N . 36) M F
S T A , C
A M M I (O S C N . 149)
S C I M A M I
(O M H N . 35) M H

附注 F (A 2022 RMB Y)		2022 RMB Y)	
V. N (I) C		B	B
I			
C		454,907.26	971,773.72

附注
F
(A 2022
RMB Y)

V. N ()

(III) A

1. A

B B

A		B	B
W 1	388,961,193.05	303,910,574.15	
1-2	4,755,919.87	9,812,859.20	
2-3	3,941,367.25	4,259,870.27	
Q 3	5,180,894.08	3,140,407.07	
S -	402,839,374.25	321,123,710.69	
L :P	20,002,683.36	9,365,835.23	
T	382,836,690.89	311,757,875.46	

T C

附注
F
(A 元)

2022
RMB Y 元

F

V. N ()

(III) A ()

2. A

↓

↓

↓

↓

B

B

↓

B

P

B

P

↓

P

P

P

P

C

A

(%)

A

(%)

B

A

(%)

A

(%)

B

P ↓

↓

I :

M ↓

P ↓

↓

18,221,975.88	4.52	12,514,142.66	68.68	5,707,833.22	7,247,978.61	2.26	4,590,286.39	63.33	2,657,692.22
18,221,975.88	4.52	12,514,142.66	68.68	5,707,833.22	7,247,978.61	50.00	4,590,286.39	63.33	2,657,692.22
384,617,398.37	95.48	7,488,540.70							

附注
F
(A 2022
RMB Y)

V. N ()

(III) A ()

2. A ()

P ↓ :

B
P P

I B (%)

M 18,221,975.88 12,514,142.66 68.68

L ECL

T 18,221,975.88 12,514,142.66 /

D ↓ : N III. (X)

P ↓ :

B
A P P

I (%)

Q 384,617,398.37 7,488,540.70 1.95

T 384,617,398.37 7,488,540.70

C ↓ : N III. (X)

附注
F
(A 人民币元)

2022
RMB Y

V. N ()

(III) A ()

3.	P						
			B		C	R	W - B
	C						
	P		4,590,286.39	8,289,230.88		365,374.61	12,514,142.66
	P		4,775,548.84	3,379,914.39		666,922.53	7,488,540.70
	T		9,365,835.23	11,669,145.27		1,032,297.14	20,002,683.36
4.	A						
	I					A	-
	A						365,374.61

附注
F
(A 2022
RMB Y)

V. N ()

(I) A

1. A

A	B			B		
	A	P	(%)	A	P	(%)
W 1	29,973,748.69		93.08	11,751,451.87		99.11
1-2	2,127,484.58		6.61	58,511.20		0.49
2-3	56,690.70		0.18	24,163.99		0.20
Q 3	43,300.00		0.13	24,300.00		0.20
T	32,201,223.97		100.00	11,858,427.06		100.00

附注
F
(A 2022
RMB Y)

V. N ()
() O

	B	B 2021
I		↓
I		↓
D		↓
O	37,195,219.68	29,925,487.99
T	37,195,219.68	29,925,487.99

(1) O ↓

	B	B 2021
A		↓
W 1	31,752,956.09	20,470,501.76
1-2	12,384,779.19	4,096,700.18
2-3	4,035,447.86	838,693.49
3-4	1,755,508.40	2,814,221.11
4-5	101,363.87	1,452,266.68
O 5	3,877,306.68	2,930,000.00
S	53,907,362.09	32,602,383.22
L : P ↓	16,712,142.41	2,676,895.23
T	37,195,219.68	29,925,487.99

附注
F
(A) 2022
RMB Y

V. N ()

() O ()

(2) O

C	B		B		B		B		B	
	A	(%)	A	(%)	B	A	(%)	A	(%)	B
P										
25,337,819.20	47.00	15,852,030.91	62.56	9,485,788.29	1,435,560.00	4.40	1,435,560.00	100.00		
I										
H										
U C										
C D										
A T, P										
C					1,435,560.00	100.00	1,435,560.00	100.00		
H Y H										
C, L	25,337,819.20	47.00	15,852,030.91	62.56	9,485,788.29					
P										
28,569,542.89	53.00	860,111.50	3.01	27,709,431.39	31,166,823.22	95.60	1,241,335.23	3.98	29,925,487.99	
I										
P	28,569,542.89	53.00	860,111.50	3.01	27,709,431.39	31,166,823.22	95.60	1,241,335.23	3.98	29,925,487.99
T	53,907,362.09	100.00	16,712,142.41		37,195,219.68	32,602,383.22	100.00	2,676,895.23		29,925,487.99

附注
F
(A 币种) 2022
RMB Y 币种)

V. N 币种 币种 币种 币种 (币种)

() O (币种)

(2) O 币种 币种 币种 币种 币种 (币种)

P 币种 币种 币种 币种 :

B
P P

N B (%)

币种 Y

H 币种 C .,L . 25,337,819.20 15,852,030.91 62.56

T 币种 25,337,819.20 15,852,030.91

D P 币种 币种 币种 币种 : P 币种 N III. (X) 币种

P 币种 币种 :

B
P P

N O (%)

P 币种 28,569,542.89 860,111.50 3.01

T 币种 28,569,542.89 860,111.50

C 币种 币种 P 币种 币种 : P 币种
N III. (X) 币种 .

附注
F
(A) 2022
RMB Y

V. N ()

() O ()

(3) D

	1	2	3
		L	
		ECL	L
	12-	(-	ECL (-
P	ECL))
1,241,335.23			1,435,560.00 2,676,895.23
- T 2			
- T 3			
- R 2			
- R 1			
P 141,793.04			15,852,030.91 15,993,823.95
R 485,492.80			1,435,560.00 1,921,052.80
W 37,523.97			37,523.97
W			
O			
B 860,111.50			15,852,030.91 16,712,142.41

附注
F
(A) 2022
RMB Y

V. N ()

() O ()

(3) D ()

C :

	1	2	3
	L		
	ECL		
B	12- ECL	(-)	L ECL (-)
31,166,823.22		1,435,560.00	32,602,383.22
- T 2			
- T 3			
- R 2			
- R 1			
A	2,428,909.82	25,337,819.20	27,766,729.02
D	4,306,570.80	1,435,560.00	5,742,130.80
O	-719,619.35		-719,619.35
B	28,569,542.89	25,337,819.20	53,907,362.09

附注
F
(A) 2022
RMB Y

V. N ()

() O ()

(4) P ↓ , ↓

	期末余额	期初余额	人民币	美元	人民币
C	↓	↓	↓	↓	-
P ↓	1,435,560.00	15,852,030.91	1,435,560.00		15,852,030.91
P ↓	1,241,335.23	141,793.04	485,492.80	37,523.97	860,111.50
T	2,676,895.23	15,993,823.95	1,921,052.80	37,523.97	16,712,142.41

O , ↓ ↓ ↓ ↓ ↓ :

D

N

H	U	C	1,435,560.00	F	R	M
C	D					
A	T	, P	C			

T 1,435,560.00

附注
F
(A 2022
RMB Y)

V. N ()

() O ()

(5) O

I A -

O 37,523.97

(6) O

B B

N

D 20,677,631.31 23,577,997.61

P 816,666.30 4,228,330.66

附
F
(A 附 2022
RMB Y 附)

V. N ()

(I) I

	B	B	B 附	B 附
T 附 附 附	3,697,607.74	3,697,607.74	2,242,027.51	2,242,027.51
C 附	54,633,789.63	54,633,789.63	54,277,273.72	54,277,273.72
T 附	58,331,397.37	58,331,397.37	56,519,301.23	56,519,301.23

(II) O

	B	B 附 附 附
I		附 附
I 附 附	196,008.48	137,228.50
P 附 附 附	269,072.88	321,191.35
P 附 附	287,243.41	348,266.00
T 附	752,324.77	806,685.85

附注
F
(A 2022
RMB Y)

V. N ()

(III) L

	B	B	B	B	D
E	14,000,000.00		14,000,000.00		
T	14,000,000.00		14,000,000.00		

(I) L -

A								
M T C.,L.	13,156,356.09		-4,287,457.64	5,310,451.69			14,179,350.14	
Y H C.,L.	58,100,000.00	500,000.00					57,600,000.00	
H M C.,L.		22,193,790.14	-1,090,147.47				21,103,642.67	
M C C.,L.	23,198,356.89		-1,102,416.10				22,095,940.79	
K H C.,L.	18,687,211.65		74,969.38	400,000.00			18,362,181.03	
C Y H C.,L.	11,514,784.92		-1,309,653.45				10,205,131.47	
J S H C.,L.	5,191,069.69				5,191,069.69			
H Y H C.,L.								
T	129,847,779.24	22,193,790.14	500,000.00	-7,714,705.28	5,310,451.69	400,000.00	5,191,069.69	143,546,246.10

N : O 10 A 2022, Z K H M (G) C.,L. (Z K), C 28% H Y H C.,L. (H Y), T W L L Y H M C.,L. (L L) RMB14,000,000.00, S A C J H C S I I E I F P (L.P.), C J P I M H S I I F P (L.P.), T W L L H M C.,L., L L L L RMB13,922,929.38 , Z K H Y 33% H Y B Y , H Y Y Y RMB8,212,142.17 C Y H Y

附注
F
(A 2022
RMB Y)

V. N ()
() O -

	B	B
I		
F	63,116,852.05	65,812,274.58
I : I	63,116,852.05	65,812,274.58
T	63,116,852.05	65,812,274.58

WENZHOU KANGNING HOSPITAL CO., LTD.
F
(A) 2022
RMB Y ()

	I	B	M	M	E	F
1. O						
(1) B	745,833,959.90	142,218,120.78	6,548,724.87	68,038,620.62	962,639,426.17	
(2) I	811,977.80	25,247,491.51	6,016,909.41	9,508,145.59	181,611,758.16	
-P	811,977.80	14,854,645.52	2,906,555.91	5,748,234.46	24,321,413.69	
-T						
-I		10,392,845.99	3,110,353.50	3,759,911.13	17,263,110.62	
-O					140,027,233.85	
(3) D	70,270,990.67	65,654,865.68	3,162,440.49	25,386,159.55	164,474,456.39	
-D		12,438,192.49	658,984.47	3,310,725.18	16,407,902.14	
-D		5,259,711.00	565,764.12	2,213,845.28		
-O	70,270,990.67	47,956,962.19	1,937,691.90	19,861,589.09	140,027,233.85	
(4) B	676,374,947.03	101,810,746.61	9,403,193.79	52,160,606.66	979,776,727.94	

附注
F
(A 2022
RMB Y)

V. N ()

(II)C

1. C	B	B	B	B
I	I	I	I	I
C	152,497,399.68	43,795,718.15		
C				
T	152,497,399.68	43,795,718.15		
2. D	B	B	B	B
I	B	I	B	I
W K T C	311,600.00	311,600.00	782,356.00	782,356.00
T N Y H			1,027,373.54	1,027,373.54
T L Y H	72,377,326.40	72,377,326.40	6,213,670.10	6,213,670.10
T P C H			7,504,860.00	7,504,860.00
T O Y H			27,288,058.64	27,288,058.64
T L C H	27,536,449.81	27,536,449.81	150,609.00	150,609.00
T Q Y H	16,073,697.42	16,073,697.42		
T J S H	35,508,167.99	35,508,167.99		
O	690,158.06	690,158.06	828,790.87	828,790.87
T	152,497,399.68	152,497,399.68	43,795,718.15	43,795,718.15

(II)C

()

3. M

I : C
A : I

P	B MB'0,000	I	D	B	(%)	P	(%)	A	(%)	I	(%)
T											
L Y H	18,003.00	6,213,670.10	66,247,515.67	72,461,185.77	40.25	40.00	1,883,479.17	1,608,608.70	4.90	0	
T											
P C H	1,897.75	7,504,860.00	17,107,073.00	24,611,933.00	100.00	100.00				0	
T											
O Y H	4,047.80	27,288,038.64	11,021,933.76	38,310,012.40	100.00	100.00				0	
T											
L C											
H	16,020.00	150,609.00	27,385,840.81	27,536,449.81	17.19	20.00				0	
T											
Q Y											
H	9,848.00		16,073,697.42	16,073,697.42	16.32	15.00				0	
T											
J											
H	6,666.00		35,508,167.99	35,508,167.99	54.15	55.00				0	
T											
		41,157,197.74	173,344,248.65	62,921,945.40			1,883,479.17	1,608,608.70			

附注
F
(A) 2022
RMB Y

V. N ()

(III) - -

B

I

1.O			
(1)B		363,270,419.51	363,270,419.51
(2)I		37,254,480.17	37,254,480.17
-N		21,847,297.56	21,847,297.56
-I		15,407,182.61	15,407,182.61
(3)D		81,876,743.78	81,876,743.78
-D		16,772,968.78	16,772,968.78
-D		65,103,775.00	65,103,775.00
(4)B		318,648,155.90	318,648,155.90
2.A			
(1)B		105,858,149.38	105,858,149.38
(2)I		38,189,335.84	38,189,335.84
-P		38,189,335.84	38,189,335.84
(3)D		15,803,080.90	15,803,080.90
-D		4,949,246.94	4,949,246.94
-D		10,853,833.96	10,853,833.96
(4)B		128,244,404.32	128,244,404.32
3.I			
(1)B			
(2)I			
(3)D			
(4)B			
4.C			
(1)C		190,403,751.58	190,403,751.58
(2)C		257,412,270.13	257,412,270.13

附
F
(A 2022
RMB Y)

V. N ()

(I) I

C

	L	M
I		
1.0		
(1)	102,977,820.17	3,061,637.13
(2)I	25,616,355.88	-3,433,306.28
-P	19,841,690.88	-4,460,006.28
-I	5,774,665.00	1,026,700.00
(3)D		1,141,970.00
-D		508,000.00
-D		633,970.00
(4)	128,594,176.05	3,061,637.13
2.A		
(1)	9,610,253.66	360,120.18
(2)I	2,889,207.41	330,465.48
-P	2,889,207.41	330,465.48
-I		726,864.91
(3)D		485,345.23
-D		39,066.67
-D		446,278.56
(4)	12,499,461.07	690,585.66
3.I		
(1)		
(2)I		
(3)D		
(4)		
4.C		
(1)C	116,094,714.98	2,371,051.47
(2)C	93,367,566.51	2,701,516.95

附
F
(A 附
2022
RMB Y 附)

B

D

I

附 附 附

附 附

附 附 附 附 附)

V. N
() G
I. C 附
N

附注
F
(A 附注 2022
RMB Y 附注)

V. N 附注 附注 附注 附注 ()

() G ()

2. I 附注 附注 附注 附注

A 附注 C 附注 附注 附注 附注 附注
附注 附注 , 附注 附注 :

U : RMB'0,000

A	31 D	2022
宁波市第一医院有限公司		927.18
杭州普康医院有限公司		69.03
嘉兴第一医院有限公司		154.90
温州南浦医院有限公司		778.49
北京第一医院有限公司		2,298.73
温州医院投资管理有限公司		15.11
杭州康康医院有限公司		506.9
常州康康普康医院有限公司		684.33
温州中心医院有限公司		1,941.63
普康常州第一医院有限公司		5,177.02
杭州第一医院投资管理有限公司		127.26
浙江富宁投资管理有限公司		32.60
江苏普康医院有限公司		506.03
T 附注		13,219.21

I 附注 附注 , C 附注 附注 附注 附注
附注 附注 () 附注 附注 . I
附注 附注 附注 附注 , 附注 附注

附注
F
(A 2022
RMB Y)

V. N ()

(II) D ()

2. D

	B	B	T	D
I				
A				
	148,564,631.76	37,141,157.94	144,340,394.12	36,085,098.53
C	13,116,852.07	1,967,527.81	15,812,274.60	2,371,841.19
O	6,620,111.12	1,439,193.06	6,958,909.45	1,418,850.23
T	168,301,594.95	40,547,878.81	167,111,578.17	39,875,789.95

(III) O -

	B	P	C	B	P	C
I	B			B	P	C
P	6,936,000.00		6,936,000.00	6,936,000.00		6,936,000.00
P	6,605,047.21		6,605,047.21	130,386.60		130,386.60
T				14,000,000.00		14,000,000.00
T	13,541,047.21		13,541,047.21	21,066,386.60		21,066,386.60

(I) -

	B	B
I		
S	195,000,000.00	200,000,000.00
G	8,000,000.00	54,050,000.00
T	203,000,000.00	254,050,000.00

附注
F
(A 2022
RMB Y)

V. N ()

() F

	年初余额	本期增加	本期减少	期末余额
I				
F		13,922,929.38		13,922,929.38
T		13,922,929.38		13,922,929.38

(I) N

	年初余额	本期增加	本期减少	期末余额
B				
B		997,944.00		997,944.00
T		997,944.00		997,944.00

(II) A

	年初余额	本期增加	本期减少	期末余额
T				
A				
W 1		84,193,738.77		55,761,620.69
1-2		1,161,389.02		2,767,905.77
2-3		71,968.47		168,509.77
O 3		345,965.27		287,110.78
T				

附注
F
(A 2022
RMB Y)

V. N ()

(III) A

	B	B
I		
A	29,436,207.46	16,275,602.70
R	458,629.04	
T	29,894,836.50	16,275,602.70

(I) C

	B	B
I		
A		3,240.59
T		3,240.59

() E

1. L	B	I	D	B
I				
S -	57,969,287.42	498,871,976.49	488,702,553.33	68,138,710.58
P -	2,518,896.85	30,311,176.43	30,410,434.15	2,419,639.13
T	60,488,184.27	529,183,152.92	519,112,987.48	70,558,349.71

附注
F
(A) 2022
RMB Y

V. N ()
() E ()

2. L -

	期末余额	期初余额	本期增加	本期减少
(1) 应付账款	56,230,979.61	447,906,594.96	437,976,426.00	66,161,148.57
(2) 应付账款	87,835.30	10,184,665.65	9,965,118.81	307,382.14
(3) 应付账款	1,334,394.89	19,527,025.66	19,397,236.12	1,464,184.43
I : M	1,290,685.28	18,813,797.48	18,678,735.17	1,425,747.59
W	38,841.61	641,567.33	643,107.24	37,301.70
M	4,868.00	55,652.85	60,096.21	424.64
O		16,008.00	15,297.50	710.50
(4) H				

附注
F
(A 2022
RMB Y)

V. N ()
(I)

	B	B
I		
VAT	2,399,813.52	2,194,179.27
E	26,859,279.46	22,060,348.34
I	1,260,918.02	1,102,372.67
C	163,205.29	39,305.94
P	2,292,516.47	4,544,055.56
E	116,587.33	28,135.83
L	387,329.69	250,083.20
S	25,663.04	16,848.52
E	1,696.00	
40 TS 1 SCN /GS0 1 0 0 1 102.		

附注
F
(A 2022
RMB Y)

V. N ()

(II) O ()

2. D

	B	B
I		
O		86,550.00
D	735,000.00	
T	735,000.00	86,550.00

3. O

	B	B
I		
P	25,932,146.03	8,703,936.40
P	7,000,000.00	15,000,000.00
W	3,682,272.62	7,166,038.37
D	1,900,552.80	1,094,722.20
C	17,695,375.57	7,496,808.30
P	4,374,261.21	4,312,000.00
A	3,673,024.53	6,981,466.40
O	6,624,054.06	4,025,654.97
T	70,881,686.82	54,780,626.64

附注
F
(A 2022
RMB Y)

V. N ()

(III) N -

	B	B 2021
I		18,200,000.00
L -	22,470,000.00	18,200,000.00
L -	99,580,000.00	
L	25,548,324.39	30,040,752.22
T	147,598,324.39	48,240,752.22

(I) L -

	B	B 2021
I		18,200,000.00

附注
F
(A 人民币) 2022
RMB Y)

V. N ()

(I) L -

	B	B
I		

L - 42,404,938.54

S

T 42,404,938.54

O : -

	B	B
I		

A 141,984,938.54

I : U 9,382,772.07

L : L - 99,580,000.00

T 42,404,938.54

(II) D

	B	I	D	B
I				R

G 9,341,683.00 303,792.00 9,037,891.00

附注
F
(A 2022
RMB Y)

V. N ()

(II) D ()

P ↓ :

A

L	期初余额 A	本期增加	本期减少 O	期末余额 A - / -
应付账款	9,341,683.00	303,792.00	9,037,891.00	A -
T	9,341,683.00	303,792.00	9,037,891.00	

(III)

I	期初余额 I (+) / (-)	本期增加 B	本期减少 C ↓	期末余额 O S - B
T	74,600,300.00			74,600,300.00

(I) C

I	期初余额 I	本期增加 D	期末余额 B
S	783,420,735.87		783,420,735.87
O			
- S	32,642,955.35	12,214,418.85	44,857,374.20
- O	22,101,704.37	4,698,718.86	26,800,423.23
T	838,165,395.59	16,913,137.71	855,078,533.30

附注
F
(A 2022
RMB Y)

V. N ()

(I) C ()

O , :

(1) F - , N IX.

(2) I 2022, RMB4,698,718.86
R S R S
I P .

() .

	本 年 末	本 年 初	变 动 增 减
I	38,399,577.13	38,399,577.13	
S	38,399,577.13	38,399,577.13	
T	38,399,577.13	38,399,577.13	

O :

I C P ' R C , C 10%
T C
50% T
-

N **F**
F 2022
(A RMB Y)

附注
F
(A 币种) 2022
RMB Y 币种)

V. N 币种 ()

(II)

1. A 币种 币种

I	A 币种	C	A 币种	C
Ma	1,366,816,938.51	1,040,114,649.97	1,202,774,377.74	897,111,635.75
O	118,086,103.74	91,857,292.80	94,655,992.09	71,320,820.01
T 币种	1,484,903,042.25	1,131,971,942.77	1,297,430,369.83	968,432,455.76

B 币种 :

I	A 币种	A 币种
R 币种	1,366,816,938.51	1,202,774,377.74
I : P 币种	305,118,303.27	267,588,282.25
T 币种	1,061,698,635.24	935,186,095.49
R 币种	118,086,103.74	94,655,992.09
I : W 币种	85,464,736.39	51,613,429.22
M 币种	3,000,000.00	2,970,297.00
R 币种	8,067,969.32	7,515,329.40
R 币种		16,043,547.63
O	21,553,398.03	16,513,388.84
T 币种	1,484,903,042.25	1,297,430,369.83

2. D 币种

T 币种

N **F**
F 2022
(A RMB Y)

V. N ()
(III)

I

A

A

附
F
(A 2022
RMB Y)

V. N ()

(L)G

I	A	A
E	106,839,736.87	92,095,322.35
C	22,821,067.41	11,791,502.03
D	12,364,390.29	10,327,372.91
R	7,928,268.21	7,688,976.40
A	7,169,511.48	7,803,052.34
A	6,366,300.00	1,222,900.00
O	5,452,608.66	5,171,123.31
A	5,226,706.30	3,986,627.45
E	4,539,506.45	2,946,383.00
E	4,412,652.14	8,414,462.03
T	4,358,637.42	2,835,174.29
P	2,798,524.34	3,204,882.36
H	2,653,266.15	4,644,062.36
C	2,527,587.52	3,580,020.08
P	2,521,353.37	1,319,556.59
O	2,099,610.09	3,313,286.64
U	1,889,937.19	1,974,023.35
P		96,657.59
O	3,917,508.51	3,956,503.74
T	205,887,172.40	176,371,888.82

附注
F
(A 人民币)

2022

RMB Y

V. N

(LI)

I	A	A
E	29,575,455.47	24,627,424.22
O	1,164,368.95	1,346,035.33
D	550,065.23	594,882.24
P	400,114.92	311,882.70
A	76,467.92	
T	68,877.00	134,907.60
C	58,690.00	
T	30,200.00	
T	19,682.96	76,999.34
U	11,090.48	
C	3,000.00	
O	1,069,974.86	870,041.96
T	33,027,987.79	27,962,173.39

(LII)F

I	A	A
I	45,149,998.30	36,267,756.91
I	11,935,506.62	14,290,203.16
L	2,761,765.05	1,691,366.88
F	-78,462.87	38,704.15
F	1,999,946.76	3,043,331.77
T	44,309,717.14	37,658,425.95

附注
F
(A 2022
RMB Y)

V. N ()

(LIII) O

I	A	A
G	14,602,195.91	13,486,446.80
A VAT	37,171.75	
F	162,213.15	133,188.26
O	106,130.00	
T	14,907,710.81	13,619,635.06

I	A	A	A - /
T	859,807.09	1,231,900.37	I -
S T	3,408,933.78	3,325,154.99	I -
S	1,018,900.00	2,270,000.00	I -
E S S B H R	973,813.11	244,079.31	I -
I D R B C 2021	638,519.98		I -
S	600,000.00	50,000.00	I -
S	600,000.00		I -
V COVID-19	440,197.00	814,795.52	I -
S H C	311,520.00	744,608.99	I -
R B W F	303,792.00	303,792.00	A -
S	300,000.00		I -
B H P B	284,000.00	284,000.00	I -
S	249,000.00		I -
S H B Y 2021	238,400.00		I -

附 表
F 附 表
(A 附 表) 2022
RMB Y 附 表)

V. N 附 表 附 表 附 表 附 表 (附 表)

(III) O 附 表 (附 表)

G 附 表 附 表 (附 表)

I	A 附 表	A 附 表	A 附 表 /
H 附 表 COVID-19 附 表			
H 附 表 C 附 表 P 附 表	197,750.00		I - 附 表
H 附 表 C 附 表 C 附 表	174,653.70		I - 附 表
U 附 表 S 附 表 B 附 表 B 附 表 H 附 表 R 附 表	138,796.96		I - 附 表
O 附 表 S 附 表	120,835.00		I - 附 表
S 附 表	117,625.00		I - 附 表
W 附 表 S 附 表 C 附 表	64,000.00		I - 附 表
H 附 表 B 附 表 Y 附 表 D 附 表, H 附 表	63,971.59		I - 附 表
I 附 表 D 附 表 R 附 表 B 附 表 P 附 表	55,332.00	50,000.00	I - 附 表
S 附 表 I 附 表 P 附 表	50,000.00		I - 附 表
S 附 表	90,000.00	168,696.99	I - 附 表
S 附 表 D 附 表 P 附 表 H 附 表	40,000.00	40,000.00	I - 附 表
T M 附 表 F 附 表 S 附 表 A 附 表 T 附 表	38,201.19		I - 附 表
E 附 表	36,218.55		I - 附 表
T 2022 附 表			
E 附 表 I 附 表 B 附 表 Y 附 表 C 附 表	22,045.69		I - 附 表
S 附 表 F 附 表 B 附 表 N 附 表 M 附 表 B 附 表 P 附 表 A 附 表	20,000.00		I - 附 表
T 附 表 W 附 表 E 附 表 E 附 表 B 附 表	20,000.00		I - 附 表
T 附 表 H 附 表 C 附 表 L 附 表 D 附 表	20,000.00		I - 附 表
T 附 表 W 附 表 E 附 表 E 附 表 B 附 表	20,000.00		I - 附 表

附注
F
(A 2022
RMB Y)

V. N ()

(III) O ()

G ()

I	A	A	A - /
R C			
D C P	17,000.00		I -
S			
E C J D	13,610.61		I -
W L D D R B ' E			
R I P	12,000.00		I -
Y C H B ' S P H S F	10,200.00	13,500.00	I -
W M H C ' F Y M			
T	7,000.00		I -
W M H C ' H R			
T F	6,700.00		I -
S W H P F M C	4,433.33		I -
P C H B ' S F	3,000.00	1,904,299.94	I -
L C C D C P ' F M			
S	3,000.00		I -
W H P F M C ' H			
P F S	1,833.33		I -
Y D P D ' F R			
C R , D B	1,600.00		I -
E A S	1,500.00	74,237.34	I -
M S	1,380.00		I -
P H S F L D H C	1,000.00		I -
P C P F E M - -C			
T HIV, S, H B	476.00		I -
P C P F F P B D			
P	450.00		I -
O D M S A ' S			
M A D R	360.00		I -

N **F**
F 2022
(A RMB Y)

附注
F
(A 2022
RMB Y)

V. N ()

(L) G

	A	A
F	-2,054,396.53	8,407,356.31
I : G		
F	-13,922,929.38	
I		1,010,034.42
T	-15,977,325.91	9,417,390.73

(L I) C

	A	A
I		
L	11,260,563.08	3,005,695.74
L	13,930,978.11	-865,499.29
T	25,191,541.19	2,140,196.45

(L II) A

	A	A
I		
G	10,345,460.56	6,179,290.37
T	10,345,460.56	6,179,290.37

附注
F
(A 人民币)

2022

RMB Y

V. N ()

(L III)G

	A	A	A
I			
G			
()	406,184.95	-101,512.90	406,184.95
I : G	406,184.95	-101,512.90	406,184.95
O		22,109.35	
T	406,184.95	-79,403.55	406,184.95

(II) N -

	A	A	A
I			
G	12,737.42	154,603.42	12,737.42
I : F	12,737.42	154,603.42	12,737.42
D	7,435,774.26	9,470,530.18	7,435,774.26
G	55,075.00	265,600.00	55,075.00
G	60.10		60.10
P	35,711.51		35,711.51
D		1,800,000.00	
V	12,000.00		12,000.00
U	15,000.00		15,000.00
O	987,619.57	145,198.20	987,619.57
T	8,553,977.86	11,835,931.80	8,553,977.86

附注
F
(A 2022
RMB Y)

V. N ()

(II) N - ()

G -

	A	A	A - /
I			-
S W -			
P W 2021		100,000.00	I -
H		150,000.00	I -
S D I S	5,000.00		I -
F C A D R			
E T C A	5,000.00		I -
S B L E H	40,000.00		I -
S B L E H	5,000.00		I -
I F P H B		15,600.00	I -
T	55,075.00	265,600.00	

(L) N -

	A	A	A
I			
L	1,587,610.46	165,976.73	1,587,610.46
I : F	1,587,610.46	165,976.73	1,587,610.46
E	3,927,631.03	3,333,396.94	3,927,631.03
	521,375.57		521,375.57
L	99,809.90		99,809.90
P	267,628.43		267,628.43
L	1,754,450.54	3,398,511.21	1,754,450.54
O	1,182,532.80	1,738,698.54	1,182,532.80
T	9,341,038.73	8,636,583.42	9,341,038.73

附注
F
(A 附注) 2022
RMB Y 附注

V. N 附注 附注 附注 附注 ()

(LI) I

1. 附注 附注

I		A	A
C	附注	40,192,565.61	26,919,820.08
D	附注	-13,618,853.12	

附注
F
F
(A 元)

2022

RMB Y

V. N ()

(LI)I

1. 资产减值准备

I	A	A
R 应收账款减值准备	40,253,328.59	45,945,728.57
G 存货减值准备	14,633,117.41	13,579,087.19
L 长期股权投资减值准备	8,067,969.32	7,012,773.24
D 固定资产减值准备	10,116,855.54	12,851,693.57
I 无形资产减值准备	12,751,158.99	14,960,534.77
N 合同资产减值准备	1,035,391.18	1,870,927.58
R 其他应收款减值准备	14,000,000.00	
T 合计	100,857,821.03	96,220,744.92

2. 合同资产减值准备

I	A	A
I 应收账款合同资产减值准备	30,632,892.49	23,313,110.97
C 合同资产减值准备	82,155,141.49	54,235,967.08
D 长期股权投资合同资产减值准备	6,608,712.31	6,714,560.33
N 其他应收款合同资产减值准备	2,927,440.32	4,469,403.02
F 其他流动资产合同资产减值准备	1,082,364.51	1,442,594.04
R 其他非流动资产合同资产减值准备	12,498,972.00	
T 合计	135,905,523.12	90,175,635.44

3. 其他非流动资产减值准备

I	B	B
N 其他非流动资产减值准备	8,770,704.43	
T 合计	8,770,704.43	

		2022	
		RMB Y	
		()	
V. N		()	
(LI)I		()	
4.	G		
	I	A	A
	G	150,684,059.10	
	G	736,190.90	
	T	151,420,250.00	
5.	G		
	I	A	A
	G	8,096,992.56	
	G	43,524,302.81	44,807,765.61
	F	4,500,000.00	750,000.00
	G		15,118,800.00
	T	56,121,295.37	60,676,565.61

附
F
(A 2022
RMB Y)

V. N ()
(L)

1. S

A A

	A	A
1. R		
N	-10,968,838.36	40,860,230.05
A : C	25,191,541.19	2,140,196.45
P	10,345,460.56	6,179,290.37
D	53,029,785.07	48,274,868.81
C		
D	38,189,335.84	41,779,572.06
A	22,991,163.56	14,530,192.10
A	46,397,646.59	38,836,785.71
L		
()	-406,184.95	79,403.55
L	1,574,873.04	11,373.31
L	15,977,325.91	-9,417,390.73
F	45,071,535.43	36,306,461.06
I	-2,850,458.27	-6,937,845.27
D	-6,345,432.93	27,745,384.58
I	672,088.86	14,843,351.28
D	-1,812,096.14	-19,010,829.84
D	-137,055,559.27	-37,743,452.80
I	127,218,378.32	-4,581,092.21
O		
N	227,220,564.45	193,896,498.48
2. S		
C		
C		
F		
3. N		
G	258,595,990.97	188,734,845.77
L : G	188,734,845.77	200,092,665.42
A : G		
L : G		
N	69,861,145.20	-11,357,819.65

附注
F
2022
(A 人民币)

V. N ()
(L)

2. N

A

54,309,855.16
I :J S H C.,L . 21,684,900.00
Y Y TCM- H C.,L . 32,624,955.16
L :C 624,153.88
I :J S H C.,L . 624,153.88
A :C
O 53,685,701.28

3. C

A A

I		
I. C	258,595,990.97	188,734,845.77
I :C	454,907.26	971,773.72
D		
C	257,534,338.59	187,484,938.31
O	606,745.12	278,133.74
D		
D		
L		
II. C		
I :B		
III. C	258,595,990.97	188,734,845.77
I :U		
G		

附注
F
(A) 2022
RMB Y

V. N ()

(L I) A

- -

C

I		R
M	498,972.00	B
	12,000,000.00	P
F	35,612,151.67	C
I	73,406,248.95	S
	6,107,838.02	C
T	133,942,408.61	

(L II) G

P N V (XLIII) N V (XLIX)

VI. C

(I) B

1. B

C P

N (%)

附注
F
(A 附注) 2022
RMB Y 附注

VI. C 附注 ()

(I) B ()

2. C 附注 附注

Y Y J 附注 S Z 附注 F

附注
2022
人民币元

VI. 关联方

(I) 关联方

2. 关联方往来余额 (人民币元)

(2) 截至2022年12月31日, 关联方往来余额如下表所示。关联方往来余额包括关联方应收、应付账款, 关联方预收、预付账款, 关联方其他应收、应付账款, 关联方其他流动资产、其他非流动资产, 关联方其他应付款、其他流动负债、其他非流动负债等。关联方往来余额的期初余额和期末余额如下表所示。关联方往来余额的期初余额和期末余额如下表所示。关联方往来余额的期初余额和期末余额如下表所示。

	2022年12月31日		2021年12月31日		2020年12月31日	
	人民币元	人民币元	人民币元	人民币元	人民币元	人民币元
应收账款	59,544,389.38	46,544,389.38	37,912,065.31	21,595,600.11	3,596,967.56	3,596,967.56
其他应收款			624,153.88	624,153.88	3,003,084.38	3,003,084.38
预付款项	3,060,406.64	3,060,406.64	7,552,399.46	7,552,399.46		
其他流动资产			505,619.01	504,706.60	590,783.18	590,783.18
其他非流动资产			22,965.97	22,965.97		
应付账款	4,043,853.80	4,043,853.80	847,808.30	394,720.51	3,100.00	3,100.00
其他应付款	13,299,835.09	299,835.09	6,651,653.69	6,651,653.69		
其他流动负债	24,864,697.08	24,864,697.08				
其他非流动负债	14,275,596.77	14,275,596.77	5,845,000.00	5,845,000.00		
长期应付款	17,960,741.79	17,960,741.79	8,244,110.73	4,164,994.43	422,980.00	422,980.00
其他非流动负债	14,710,741.79	14,710,741.79	4,099,565.00	4,099,565.00	261,041.74	261,041.74
其他流动负债			618,827.28	618,827.28	159,133.43	159,133.43
其他非流动负债			-553,397.85	-553,397.85	2,804.83	2,804.83
其他非流动负债	3,250,000.00	3,250,000.00	4,079,116.30			
关联方往来余额	41,583,647.59	28,583,647.59	29,667,954.58	17,430,605.68	3,173,987.56	3,173,987.56
关联方往来余额			15,130,745.84	8,889,661.19	500,000.00	500,000.00
关联方往来余额	41,583,647.59	28,583,647.59	14,537,208.74	8,540,944.49	2,673,987.56	2,673,987.56

关联方往来余额的期初余额和期末余额如下表所示。关联方往来余额的期初余额和期末余额如下表所示。关联方往来余额的期初余额和期末余额如下表所示。

附
F
(A 表)
2022
RMB Y 元

VI. C
(II) D

1. L

项目	2022年7月31日	2022年7月31日	2022年7月31日	2022年7月31日
人民币元	人民币元	人民币元	人民币元	人民币元
流动资产	14,000,000.00	28.00	42,078,792.16	33.00
非流动资产			16,500,000.00	16,500,000.00
总资产			58,578,792.16	49.50
流动负债				
非流动负债				
总负债				
所有者权益				
实收资本				
资本公积				
盈余公积				
未分配利润				
所有者权益合计				
总资产				
总负债				
所有者权益				

2022年7月31日，公司总资产为58,578,792.16元，其中流动资产为14,000,000.00元，非流动资产为16,500,000.00元。总负债为0元，所有者权益为58,578,792.16元。所有者权益中，实收资本为0元，资本公积为0元，盈余公积为0元，未分配利润为58,578,792.16元。

2022年7月31日，公司总资产为58,578,792.16元，其中流动资产为14,000,000.00元，非流动资产为16,500,000.00元。总负债为0元，所有者权益为58,578,792.16元。所有者权益中，实收资本为0元，资本公积为0元，盈余公积为0元，未分配利润为58,578,792.16元。

附注
F
(A 人民币元) 2022
RMB Y)

VI. C ()

(III) C

T 人民币元, C 人民币元 47.48% H 人民币元 RMB7.23 . A H 人民币元

N **F**
 F 2022
 (A RMB Y)

VII.I

(I) I

1. S G

(%)

N P P N (0000') D I M

附 表
F
(A 表) 2022
RMB Y 元)
VII.I ()

(I) I ()

1. S G ()

N	P	P	N	(0000')	D I M (%)		
					D	I	M
Z Y H T Y LLC	H	H	T Y	2,040.82		98.00	I
C.,L.							
W Y D C.,L. LLC	W	W	D	50		100.00	I
Y M H E-H LLC	W	W	H	500		100.00	I
(W)C.,L.							
Z D P LLC	W	W	P	1,000		80.00	I
C.,L.							
C K P LLC	C	C	M	2,700		64.55	B
H C.,L.							
C Q I K LLC	H	H	M	1,000		100.00	I
H C.,L.							
H Y M E LLC	H	H	T Y	500		100.00	I
R&DC.,L.							
H Y N S LLC	H	H	N	100		100.00	I
C.,L.							
L C H C.,L. LLC	T	T	M	5,000		100.00	I
S Y H LLC	S	S	M	6,000		55.00	I
P Y H H LLC	J	J	M	1,660		100.00	I
C.,L.							
(浦江怡寧黃鋒醫院有限公司)							
C K H LLC	H	H	M	1,000		100.00	I
H C.,L.							
C K H C.,L. LLC	C	C	M	5,000	100.00		I
C Y N C LLC	C	C	M	1,000		100.00	I
C.,L.							
Y K H C.,L. LLC	Y	Y	M	100	100.00		I
L K H C.,L. LLC	T	T	M	200	80.00		I
O Y E H C., LLC	W	W	M	1,000	100.00		I
L.							
Q K H C.,L. LLC	L	L	M	3,200	100.00		I
S Y M I LLC	S	S	M	1,000	100.00		I
C.,L.							


N **F**
 F 2022
 (A RMB Y)

Name	Type	Shareholder	Shareholding Amount (0000')	Shareholding Ratio (%)		
				Direct	Indirect	Total
Wenzhou Kangning Hospital Co., Ltd. LLC	W	W	2,585.98	100.00	B	W Kangning Hospital Co., Ltd.

VII.I

(II) I

3. *Mother*

2022
RMB Y

	W	L	Y	H	C.,L.	B	C	N	C	N	C	N	T	C	N	T	
Y H	19,028,799.19	98,436,498.17	117,465,297.36	20,546,971.67	45,000,000.00	65,546,971.67	17,869,229.47	32,881,657.54	50,750,887.01	3,824,900.47						3,824,900.47	
B Y																	
H C.,L.	10,169,929.61	8,893,422.97	19,063,352.58	14,393,845.02	1,002,833.33	15,396,678.35	3,758,467.94	15,734,695.01	19,493,162.95	8,024,455.59	2,551,303.77					10,577,759.36	
S Y																	
H	14,488,059.45	19,086,594.25	33,574,653.70	34,702,233.46	5,720,723.50	40,422,976.96	11,484,646.25	30,441,596.64	41,926,242.89	29,993,444.43	12,842,112.65					42,834,557.08	

	W	L	Y	H	C.,L.	B	C	N	C	N	C	N	T	C	N	T
Y H																
B Y																
S Y																

N F
F 2022
(A RMB Y)

VIII. R

D , C : ,
(,). T
C :

T C ,
C . T C
C . T
, . T C
C
. T C S R M C
. T S R M C
,
C T C A C .

T C
 ,
 .

(I) C

C C

T C , , , .

T C -
 . T C
 .

附注
F
(A 2022
RMB Y)

VIII. R ()

(I) C ()

T C ,
. A
C . T C
. F
C
F , C
. T 2-9
C . S
C A B D P ' F
. T C

(II) L

L
I C . L
C B ,
12 ,
C . A
V C
:

	C B				
I	1	1-2	2-5	O	5
N	997,944.00				997,944.00
B B	211,396,818.18	223,154,176.00	153,052,040.00	69,285,680.00	656,888,714.18
L -	99,580,000.00	28,954,752.75	26,076,534.51		154,611,287.26
T	311,974,762.18	252,108,928.75	179,128,574.51	69,285,680.00	812,497,945.44

附注
F
(A 2022
RMB Y)

VIII. R ()

(II) L ()

I	I	B				O 5	T
		W 1	1-2	2-5			
		1	2	3	4		
B B		254,050,000.00					254,050,000.00

N **F**
F 2022
(A RMB Y)
VIII. R ()
(III) M ()

N **F**
F 2022
(A RMB Y)

VIII. R ()

(III) M ()

3) O

O
2022, RMB1,893,506

T C RMB1,893,506, 3%,

O 31 D 2022, RMB1,893,506, 3%,

IX. D

T

L 1 () C

L 2 L 1

L 3

T

附 表
F
2022
(A 类 非 公 开 发 行 有 限 公 司)
RMB Y 元

IX. D 非 同 业 存 款 (元)

(I) C 同 业 存 款

I	C		
	M L 1	M L 2	M L 3
I. C			
F			10,641,026.00
1. F			10,641,026.00
(1)			
(2) I			10,641,026.00
(3)			
2. F			
T			10,641,026.00
			13,922,929.38
1.			13,922,929.38
(1)			
(2)			
(3)			13,922,929.38
2. F			
T			13,922,929.38

(II) Q 同 业 拆 借

1.	3		
	M L 1	M L 2	M L 3
M			
2.			
M			
C			
C			
C			
T			
N III, (XXXI)			

N F

F 2022
(A RMB Y)

X. R

() I

T C :G W ,Wa L .

() I

D C N VII.I .

() I

F C N VII.I

T C :

N C

C H K H C ,L .	A C
W A P C ,L	A C
C Y H C ,L .	A C
H Y H C ,L .	A C

附注
F
(A 2022
RMB Y)
X. R ()

(I) I

N	C
Y M H C	N - C
N M B P A K Pa C	
I M Pa (L L Pa)	
N F T Z S	
I T C.,L	
S F H M C.,L	N - C
W L	N - C
Q K	N - C
W H	D , C
Z T E C	N - C
C.,L	

() I

1. R	C	A	A
S /			
Y M H C	M	3,000,000.00	3,000,000.00
C H K H C.,L		71,199.48	
W A P C.,L		54,281.47	456,272.70
J S H C.,L			2,372,524.98
R			682,184.79

附 表

附 表 2022
(A 股 上 市 公 司 年 度 报 告 附 录)
RMB Y 元

X. R 元 ()

() I ()

2. L 元

T C 元 :

R 元

N

T_Y 元

Y

N F T Z S I 元

T C , L .

P 元

24,380.95

T C 元 :

A

A

R 元

元

元

元

元

元

元

元

元

I

I

I

I

元

元

元

元

T_Y 元

N

元

R 元

元

Z T 元

E 元

C

H 元

C , L .

1,089,194.31

260,402.86

附注
F
2022
RMB Y

X. R ()
() I ()

3. R
T C :

	G	C	E
Y K H C.,L .	50,200,000.00	2019/8/26	2029/8/20 N
Q K H C.,L .	45,000,000.00	2019/12/31	2024/12/31 N

T C

	G	C	E
G W W L	30,000,000.00	2020/6/30	2027/6/30 N
G W , W H W L	75,000,000.00	2021/11/29	2028/11/29 N
G W , W H , W L X	150,000,000.00	2020/10/26	2026/10/25 N
G W , W L W H	200,000,000.00	2020/9/17	2023/9/17 N

4. A
C A
9

N **F**
 F 2022
 (A RMB Y)
 X. R ()

非经常性损益

2022
RMB Y

X. R ()

(II)E (C)

I 2021, , :

	C			B O			T
N	E	S	Y	B	O		T
E							
G W	-	398,742.00	15,795.90	78,916.40	4,300.00		497,754.30
W L Y	-	375,592.00	-	46,714.60	44,680.00		466,986.60
W H Y	-	208,108.00	-	42,396.60	1,200.00		251,704.60
N -							
L L	-	-	-	-	-		-
Y Y	-	28,200.00	4,986.80	32,385.97	8,932.90		74,505.67
I							
Z X	70,000.00	-	-	-	-		70,000.00
Z W	70,000.00	-	-	-	-		70,000.00
L N	70,000.00	-	-	-	-		70,000.00
H J	-	-	-	-	-		-
Q C	-	-	-	-	-		-
C J	-	-	-	-	-		-
S F	-	-	-	-	-		-
X T	-	82,613.40	8,885.40	54,030.60	18,936.60		164,466.00
T	210,000.00	1,093,255.40	29,668.10	254,444.17	78,049.50		1,665,417.17

附注
F
(A 附注 2022
RMB Y 附注)

X. R 附注 附注 附注 附注 附注 附注 附注 ()

(III) F I H

I 2022, 附注 附注 附注 附注 附注 附注 附注 2 (2021: 3),
附注 附注 附注 :

	A 附注	A 附注
I		附注
W 附注 附注 , , 附注 附注 附注	3,764,039.10	3,424,382.50
S 附注 - 附注 附注	4,109,519.26	4,411,564.18
T 附注	7,873,558.36	7,835,946.68
	N	N
		附注 附注
500,000-1,000,000.00	1	1
0 1,000,000.00	4	4
T 附注	5	5

非经常性损益

非经常性损益 2022
(A 人民币元)

XI. 少数股东权益

(I) 少数股东权益

本期少数股东权益变动情况如下：

公司于 2018 年 10 月 13 日，经 2018 年第三次临时股东大会审议通过，向特定对象发行人民币普通股 24,600,000 股，发行价格为每股人民币 10.00 元，募集资金总额为人民币 246,000,000.00 元，扣除发行费用后，募集资金净额为人民币 246,000,000.00 元。上述募集资金已于 2018 年 10 月 29 日全部到位，并经会计师事务所出具验资报告。截至 2018 年 12 月 31 日，上述募集资金已全部用于支付发行费用。截至 2018 年 12 月 31 日，上述募集资金已全部用于支付发行费用。截至 2018 年 12 月 31 日，上述募集资金已全部用于支付发行费用。

N **F**
F 2022
(A RMB Y)

XII.C **C**

(I)

1. C

附 表 F
附 表 F
(A 股 2022
RMB Y 元)

XIV. 其他综合收益

其他综合收益的期初余额为：

- 其他综合收益 C 类 2021 年 12 月 31 日 余额 为 1,000.00 元 ；

- 其他综合收益 D 类 2021 年 12 月 31 日 余额 为 1,000.00 元 。

其他综合收益 C 类 2022 年 12 月 31 日 余额 为 1,000.00 元 。 其他综合收益 D 类 2022 年 12 月 31 日 余额 为 1,000.00 元 。 其他综合收益 C 类 2022 年 12 月 31 日 余额 为 1,000.00 元 ， 其他综合收益 D 类 2022 年 12 月 31 日 余额 为 1,000.00 元 。

其他综合收益 C 类 2022 年 12 月 31 日 余额 为 1,000.00 元 。

其他综合收益 D 类 2022 年 12 月 31 日 余额 为 1,000.00 元 。

B 类 2022 年 12 月 31 日 余额 为 1,000.00 元

其他综合收益

D 类 / 其他综合收益

49.73%

46.16%

附注
F
(A 2022 RMB Y)

XV. O

(I) C

R

A 38 M T S B D E M T
S S C C P R C P
A E ,
2021 :

C	P	P	A	C
I	B R	O		-9,203,741.45
		I		12,877.91
		U		9,190,863.54

(II) I

E C
. D
C

A C W G I J 2021, C

(III) O

1. I

O A 14, 2023, 38 B D W K
H C, L ,





















附注
F
(A 2022
RMB Y)

XV. O ()

(III) O ()

1. I ()

(3) R

本
S 2022, :
:

附注 : I C C
, C
, A
C
.

A : B
C C
, ,
C C . T
C

N **F**
F 2022
(A RMB Y)

XV. O ()

(III) O ()

2. A ()

(2) I , C
12 2019, 2020 2021
2020 2021
C
2020 2021. T
RMB428,900 2020 RMB335,100 2021, C
C
2020 2021.

(3) O , C
2022

XVI. N

(I) A

1. A

B Ba

A	B	Ba
W 1	49,024,983.98	40,904,137.67
1-2	709,878.26	1,282,268.26
2-3	1,158,221.95	2,748,299.92
O 3	2,748,299.92	1,204,242.08
S	Over 3 years	1,158,221.95

附注
F
(A 币种) 2022
RMB Y 币种

XVI. N 币种 ()

(I) A ()

2. A 币种 ()

A 币种 :

B
A P P

I (%)

Q 币种 48,767,668.85 487,676.69 1.00

T 币种 48,767,668.85 487,676.69

3. P 币种 , 币种
币种

C

附 表
F
(A 类 股 份)
2022
RMB Y 元

XVI. N 非 同 步 增 发 的 普 通 股 份 的 收 入 和 成 本 (续)

(II) O

	B	B 类 股 份
I		▼ 1,000.00
I		▼ 1,000.00
D▼	53,000,000.00	
O	547,014,558.58	492,034,884.26
T	600,014,558.58	492,034,884.26
1. D▼		
	B	B 类 股 份
		▼ 1,000.00
G 类 股 份	H 类 股 份 C ., L .	33,000,000.00
Y 类 股 份	H 类 股 份 C ., L .	10,000,000.00
Q 类 股 份	H 类 股 份 C ., L .	10,000,000.00
S 类 股 份		53,000,000.00
L : P ▼		

N
F
(A)

F
2022
RMB Y)

)

(
)

)

)

)

)

(.)

)

XVI, N
(II) O

附 表
F 2022
(A 人民币)

XVI. N ()

(II) O ()

(3) P ↓

	1 12- ECL	2 L ECL (N)	3 L ECL (C -)
P			
B 123,061.04	123,061.04		123,061.04
B /			
- T 2			
- T 3			
- R 2			
- R 1			
P 103,420.62	103,420.62		103,420.62
R			
W			
W			
O			
B 226,481.66	226,481.66		226,481.66

C ↓ ↓ :

	1 12- ECL	2 L ECL (N)	3 L ECL (C -)
B 492,157,945.30	492,157,945.30		492,157,945.30
B /			
- T 2			
- T 3			
- R 2			
- R 1			
A 55,083,094.94	55,083,094.94		55,083,094.94
D			
O			
B 547,241,040.24	547,241,040.24		547,241,040.24

附注
F
(A 附注) 2022
RMB Y 附注

F

XVI. N

(II) O

(4) P

	附注	附注	附注	附注	附注	附注	附注
C							
P		123,061.04		103,420.62			226,481.66
T		123,061.04		103,420.62			226,481.66

(5) O

	附注	附注	附注	附注	附注	附注	附注
A					507,207,052.64		481,560,443.31
P					33,132,118.55		8,954,970.91
D					5,933,350.00		854,300.00
O					968,519.05		788,231.08
T					547,241,040.24		492,157,945.30

附
F
(A 2022
RMB Y)

XVI. N ()

(III) L -

	B	P	B	B	P	B
I	B	P	B	B	P	B
I	649,079,592.72		649,079,592.72	613,070,215.90		613,070,215.90
I	92,882,992.81		92,882,992.81	71,256,356.09		71,256,356.09
	741,962,585.53		741,962,585.53	684,326,571.99		684,326,571.99

1. I

	B	P	I	D	B	P	I
I	B	P	I	D	B	P	I
S Y M I C.,L.	10,354,979.06				10,354,979.06		
Z H H M C.,L.	34,627,432.36			34,627,432.36			
W K J F C	500,000.00				500,000.00		
Z K H M C.,L.	203,344,031.86	1,322,222.01			204,666,253.87		
C K H C.,L.	51,982,515.15	715,222.35			52,697,737.50		
Y K H C.,L.	1,832,112.13	301,146.25			2,133,258.38		
Y K H C.,L.	27,447,511.21	239,581.90			27,687,093.11		
Q K H C.,L.	32,626,079.15	230,565.10			32,856,644.25		
L K H C.,L.	2,110,854.98	188,216.41			2,299,071.39		
W C H C.,L.	53,500,000.00				53,500,000.00		
W L Y H C.,L.	30,000,000.00				30,000,000.00		
W O Y R H C.,L.	10,000,000.00				10,000,000.00		
P C Y H C.,L.	154,744,700.00				154,744,700.00		
J S H C.,L.		26,684,900.00			26,684,900.00		
Y Y T							
W M H C.,L.		40,954,955.16			40,954,955.16		
T	613,070,215.90	70,636,809.18	34,627,432.36		649,079,592.72		

附
F
(A
2022
RMB Y

XVI. N

(I)

1. R

	A	C	A	C
M	337,586,514.02	264,978,847.50	365,462,139.23	270,930,179.07
O	5,554,936.61	45,300.00	4,336,166.89	559,209.63
T	343,141,450.63	265,024,147.50	369,798,306.12	271,489,388.70

A :

	A	A
P	90,612,303.06	93,506,118.66
T	246,974,210.96	271,956,020.57
T	337,586,514.02	365,462,139.23

2. D
T

() I

	A	A
I	54,584,000.00	1,980,000.00
I	-5,377,605.11	-3,485,811.81
I	-18,462.42	
I	714,348.18	6,429,189.35
T	49,902,280.65	4,923,377.54

Definitions

CSRC	中國證券監督管理委員會
D ()	() 中國
D S ()	人民幣 () 中國 人民幣 1.00 , RMB 人民幣 S
G H	溫州怡寧老年醫院有限公司 (Wenzhou Yining Old People's Hospital Co., Ltd.), PRC 寧 2, 2015, C
G	C
G Y H	冠縣怡寧醫院有限公司 (Guanxian Yining Hospital Co., Ltd.), PRC 寧 1, 2017, C
HS ()	香港證券及期貨委員會 () RMB1.00 , M B H K S E
H C H	杭州慈寧醫院有限公司 (Hangzhou Cining Hospital Co., Ltd.), PRC 寧 18, 2017, C
H Y H	杭州怡寧醫院有限公司 (Hangzhou Yining Hospital Co., Ltd.), PRC 寧 25, 2016, C . O J 30, 2022, C 28% H Y H T W L L H M C , L . (桐鄉烏鎮蓮芯蓮意健康管理有限公司). U 33% H Y H
H Y H	荷澤怡寧精神病醫院有限公司 (Heze Yining Psychiatric Hospital Co., Ltd.), PRC 寧 6, 2017, C
HK\$ HKD	香港

Definitions

H K

H K S A R

PRC

H K L R

Definitions

Nanjing Yihuan Hospital	Nanjing Yihuan Hospital Co., Ltd. (南京怡寧醫院有限公司), a PRC company established on July 22, 2018, and is a wholly-owned subsidiary of the Company.
Ningbo C	Ningbo C
Ningbo A	Ningbo A, established on May 11, 2015, is a wholly-owned subsidiary of the Company.
Pudong Yihuan Hospital	Pudong Yihuan Hospital Co., Ltd. (浦江怡寧黃鋒醫院有限公司), a PRC company established on September 3, 2018, and is a wholly-owned subsidiary of the Company.
PRC Company	PRC Company, established in Hangzhou, Zhejiang Province, PRC, on May 28, 2013, and is a wholly-owned subsidiary of the Company.
PRC Company	PRC Company, established in Hangzhou, Zhejiang Province, PRC, on May 28, 2013, and is a wholly-owned subsidiary of the Company.
P	P, established on November 10, 2015, is a wholly-owned subsidiary of the Company.
Qiantian Kangning Hospital	Qiantian Kangning Hospital Co., Ltd. (青田康寧醫院有限公司), a PRC company established on August 1, 2011, and is a wholly-owned subsidiary of the Company.
Qiyuan Hospital	Qiyuan Hospital Co., Ltd. (衢州怡寧醫院有限公司), a PRC company established on November 20, 2015, and is a wholly-owned subsidiary of the Company.

Definitions

T R P R P	于 2022 年 12 月 31 日
R C	人民币
RMB	人民币 (PRC)
SFO	深圳证券交易所 (深交所) (股票代码: 300571) (香港)
S ()	S () 人民币 1.00 元, D S () HS ()
S ()	() S ()
S Y H	S Y H (深圳怡宁医院, S Y H C., L. (深圳市怡宁医院有限公司)), S 22, 2014, C -
S R M C	S R M C B C O (C 622 H K)
()	H K L R
S ()	S C
S C	C S C PRC C
T K H	T K H C., L. (台州康宁医院有限公司), PRC J 30, 2016, C -

Definitions

W N H W N P S H C ., L . (溫嶺南方精神疾病專科醫院
 有限公司), PRC J 20, 2018,
 C T1 T -05.4175 -30538T (°)T 0.556 -0.

